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ABSTRACT 
 Heterogeneity describes any variability across different datasets. In genomic 
studies which profile gene expression levels, the presence of heterogeneity is ubiquitous, 
and may bring challenges to the integrative analysis of multiple datasets. Thus, many 
efforts are needed to understand and address the impact of heterogeneity. In this 
dissertation, I have developed novel statistical models and computational software for 
this purpose. I derived reference-batch ComBat and ComBat-Seq, two improved models 
based on the state-of-the-art method, ComBat, for addressing one particular type of 
heterogeneity known as the “batch effects”. I showed their benefits compared to the 
existing methods in several data types and situations, and implemented these models in 
publicly available software. Then, I created systematic simulations to explore the impact 
of common study heterogeneity on the independent validation of genomic prediction 
models, showing that the most identifiable sources of heterogeneity are not the primary 
ones affecting the validation of genomic predictors. Finally, I adapted a solution using 
cross-study ensemble learning to train predictors with generalizable independent 
performance, to address the unwanted impact of batch effects on prediction. I compared 
 
 vii 
this new framework with the traditional approach for batch correction, showing that 
cross-study learning may provide a more robust-performing model in independent 
validation. Results in this dissertation provide insights and guidelines for working with 
heterogeneous gene expression profiling datasets in practice, and encourage further 
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Chapter 1. Introduction 
Heterogeneity in genomic data 
 The past few decades have witnessed the fast development of personalized 
medicine. Thanks to the advancing high-throughput technologies, a massive amount of 
biomedical data has been generated (Soon et al., 2013, Shen et al., 2014, Reuter et al., 
2015, Van Dijk et al., 2014). These data can be used for many purposes, including 
understanding biological mechanisms, classifying molecular subtypes of disease, or 
predicting disease prognosis or response to treatment. With the increasing variety and 
volume of data comes the great potential to jointly use different data for achieving these 
purposes, developing targeted treatment based on individual genetic and molecular 
information, and improving healthcare and medicine. To fulfill such potential, it is 
critical to understand the impact of heterogeneity on the joint analysis of data. 
 In meta-analysis, a field in which multiple studies are brought together for 
systematic review, heterogeneity refers to any variability among the studies (Higgins et 
al., 2011). Here, we slightly extend its definition beyond meta-analysis to any analysis of 
the data, but still use it to describe any variability across different datasets, including 
different studies, and different subsets in the same study. 
 The presence of heterogeneity is prevalent in genomic studies, caused by 
complicated biological and/or technical reasons, and it imposes great challenges in 
obtaining useful information from data. One illustrative example can be found in The 
Cancer Genome Atlas (TCGA) (Tomczak et al., 2015). The TCGA project contains a 




multiple platforms are used. For example, RNA expression has been measured with 
RNA-Seq and several microarray platforms including Agilent G4502A, Affymetrix HG-
U133A, and Affymetrix Human Exon 1.0 ST, to name a few. Samples within each 
platform were often generated in multiple batches. These differences in data types, 
platforms, batches, and even the underlying biological processes affect the statistical 
distributions of data, which brings problems to researchers wanting to do quantitative and 
integrative analyses. For instance, microarrays typically measure transcription levels on a 
continuous scale, while RNA-Seq studies contain discrete, over-dispersed count data. 
Therefore, different probabilistic modeling may be required. 
 Though heterogeneity plays an important role, many efforts are needed to fully 
understand its impact on data analysis. In this dissertation, we present work which 
address the challenges brought by heterogeneity on analyzing genomic data. We focus 
primarily on gene expression profiling data, which has been generated in microarray, 
RNA-Seq, and now more commonly, single-cell RNA-Seq platforms. We mainly 
consider the impact of heterogeneity on two tasks, namely 1) identifying differentially 
expressed genes between biological groups, and 2) developing and validating prediction 
models with genomic data. Other common tasks such as clustering of biological samples 
are also briefly mentioned. 
Batch effects and adjustment  
 One particular type of heterogeneity is known as “batch effects” (Leek et al., 
2010). Due to the cost of the experiments or the difficulty in collecting samples, genomic 




This often results in discrepancies in the statistical distributions across data from different 
technical processing batches. These batch effects can have unfavorable impact on 
downstream biological analysis. In particular, the presence of batch effects may reduce 
the benefits of integrating batches of data to increase the inferential power, e.g. in 
differential expression detection, to discover relevant biology from the combined data. It 
is therefore necessary to develop effective methods for batch effect adjustment. 
 Many of such methods have been proposed. The earliest batch effect methods 
relied on singular value decomposition (SVD) (Alter et al., 2000), machine learning 
classification approaches (DWD) (Benito et al., 2004), or a block linear model XPN 
(Shabalin et al., 2008). These methods are not flexible enough to handle multiple 
experimental conditions, or studies with unbalanced designs. More recent and flexible 
methods rely on robust empirical Bayes regression (ComBat) (Johnson et al., 2007), the 
efficient use of control samples (RUV) (Gagnon-Bartsch and Speed, 2012), or more 
complicated decomposition of data (SVA) (Leek et al., 2012). For RNA-Seq studies, 
ComBat remains one of the most popular batch adjustment methods when the effects 
come from known sources, while SVASeq (Leek, 2014) and RUVSeq (Risso et al., 2014) 
are commonly used when the source of effects is unknown. Methods designed for 
specific downstream tasks have also been proposed. For differential expression using 
RNA-Seq data, many common methods or procedures (e.g. edgeR (Robinson et al., 2010) 
and DESeq2 (Love et al., 2014)) suggest to include batch variables as covariates in the 




 Despite the existing approaches for batch effect adjustment, there are still gaps to 
be bridged for specific data types and batch adjustment situations. In Chapter 2, we 
discuss one particular established method, ComBat (Johnson et al., 2007). We explain its 
limitations in several data types and situations, and present alternative methods to 
improve its utility and flexibility. 
Training genomic predictors with generalizable performance 
 Besides the inference of differentially expressed genes, another important task for 
personalized medicine is to predict biological phenotypes, such as disease progression 
status or response to interventions. In this area, statistical learning models based on 
genomic information have been widely used across several disease and therapeutic areas, 
including cancer (Golub et al., 1999, Riester et al., 2014, Silvestri et al., 2015, 
Papaemmanuil et al., 2016) and infectious diseases (Seib et al., 2009, Leong et al., 2018). 
These models have great potential in facilitating clinical and preventative decision 
making (Badani et al., 2015). But to achieve such potential, it is critical to establish that 
the prediction models have generalizable performance beyond their original development 
study, so that they are able to be translated from academic setting to clinical use 
(Marchionni et al. 2008).  
 The presence of heterogeneity makes it challenging to develop predictive models 
with generalizable performance. In particular, it is well-established that cross-study 
validation performance of genomic classifiers is often inferior to internal cross-validation 
(Ma et al., 2014, Chang and Geman, 2015, Bernau et al., 2014), due to heterogeneity 




responsible for this loss of performance may provide practical implications on the 
validation of genomic predictors. In Chapters 3 and 4, we will discuss this topic, and 
provide solutions to training predictors with generalizable performance, when multiple 
studies or batches of datasets are available. 
Dissertation aims 
 The aims we present here seek to understand and address the impact of 
heterogeneity on genomic data analysis, by developing novel methods and software. 
Through these aims, we hope to provide insights and guidelines on working with 
heterogenous genomic data in practice. By providing software and publicly available 
code to reproduce the results, we would like to encourage future explorations on data 
heterogeneity, and promote the advancement of personalized medicine. 
Aim 1. Improving ComBat batch effect adjustment method for flexible data types and 
situations 
 In Chapter 2, we start from addressing the impact of batch effects on differential 
expression analysis, and propose novel models to address the limitations of one of the 
most popular methods, ComBat (Johnson et al., 2007). We propose two alterative 
models. The first is reference-batch ComBat, which selects one batch as a reference, and 
adjust the other batches to the distribution of the reference. It is useful for profiling the 
activity level of biological pathways from controlled experiments to patient data, and also 
for developing and validating fixed biomarkers. The other is ComBat-Seq, which targets 
RNA-Seq count data. We evaluate the benefits of using negative binomial distributions to 




remove batch effects. For both models, we provide simulations and real data examples to 
show their utility. We also implement these methods in user-friendly software. 
Aim 2. The impact of sources of heterogeneity on loss of accuracy from genomic 
prediction models 
 From Chapter 3, we extend our discussion to the more general data heterogeneity, 
and shift the focus from differential expression to prediction tasks. In this chapter, we 
investigate the impact of common sources of study heterogeneity on the independent 
validation of predictors. Following the findings from previous research (Bernau et al., 
2014), we provide realistic simulations based on a multi-step bootstrap framework, and 
reduce heterogeneity from each source being investigated. We then train predictors on the 
simulated data, and compare their performances before and after reducing the 
heterogeneity, in order to identify the source responsible for the performance loss from 
within to across studies. We consider 3 sources of heterogeneity: the imbalances in the 
prevalence of clinical and pathological covariates, the differences in gene covariance, and 
the differences in the “true” model that associates gene expression and clinical factors to 
outcome. Through this investigation, we provide a systematic methodology for 
quantifying the impact of heterogeneity on prediction performances. 
Aim 3. Addressing unwanted batch effects in prediction via ensemble learning 
 Then in Chapter 4, we introduce a solution to developing genomic predictors with 
generalizable performances on independent data, using cross-study learning (Patil and 




on binary classification, and compare it with the more traditional methods for batch 
effects, which is to merge the batches and then apply specifically designed software. We 
designed realistic simulations to compare the two strategies, and also applied both in 
predicting the progression status of tuberculosis in a collection of public data. Our 





Chapter 2. Improving ComBat batch effect adjustment method for flexible data 
types and situations 
Adapted from the following manuscripts: 
1. Zhang, Y., Jenkins, D. F., Manimaran, S., and Johnson, W. E. (2018). Alternative 
empirical Bayes models for adjusting for batch effects in genomic studies. BMC 
bioinformatics, 19(1):262. https://doi.org/10.1186/s12859-018-2263-6 (This 
article is distributed under the terms of the Creative Commons Attribution 4.0 
International License: http://creativecommons.org/licenses/by/4.0/. Changes to the 
article are made to fit in the context of this dissertation.) 
2. Zhang, Y., Parmigiani, G., and Johnson, W. E. (2020). ComBat-Seq: batch effect 
adjustment for RNA-Seq count data. bioRxiv, 904730 
Introduction 
 The presence of batch effects, or unwanted variation across data from different 
batches, often reduces the benefits of integrating batches of data to increase the statistical 
power for differential expression. Prior studies have clearly established the need for batch 
effect correction (Kupfer et al., 2012, Luo et al., 2010). The impact of batch effects is 
challenging, and often cannot be fully addressed by normalization methods. The 
differences in the overall expression distribution of each sample across batch may be 
corrected by normalization methods, such as transforming the raw counts to (logarithms 
of) CPM, TPM, or RPKM/FPKM, the trimmed mean of M values (TMM, Robinson and 
Oshlack, 2010), or relative log expression (RLE, Risso et al., 2014). However, batch 




(coverage) in each sample, cannot be fully corrected with normalization. An example of 
composition batch effects in microarray data was shown (Leek et al., 2010) in previous 
research. In this example, while the overall distribution of samples may be normalized to 
the same level across batches, individual genes may still be affected by batch-level bias. 
Such batch effects cannot be corrected with normalization, and require specifically 
designed software. 
 ComBat (Johnson et al., 2007) is a flexible and straightforward approach to 
remove technical artifacts due to processing facility and data batch. ComBat has been 
established as one of the most common approaches for combining genomic data across 
experiments, labs, and platforms (Lazar et al., 2012), and has been shown to be useful for 
data from a broad range of types and biological systems (Kitchen et al.,2010, Sîrbu et al., 
2010). The ComBat batch adjustment approach assumes that batch effects represent 
systematic shifts in the mean or variability of genomic features for all samples within a 
processing batch. ComBat assumes the genomic data (𝑦𝑔𝑖𝑗) for gene 𝑔, batch 𝑖, and 
sample 𝑗 (within batch 𝑖) follows the model: 
𝑦𝑔𝑖𝑗 = 𝛼𝑔 + 𝑋𝑖𝑗𝛽𝑔 + 𝛾𝑔𝑖 + 𝛿𝑔𝑖 𝑔𝑖𝑗  
𝛼𝑔 is the overall gene expression. 𝑋𝑖𝑗 is a known design matrix for sample conditions, 
and 𝛽𝑔 is the vector of regression coefficients corresponding to 𝑋𝑖𝑗. 𝛾𝑔𝑖  and 𝛿𝑔𝑖 represent 
the additive and multiplicative batch effects of batch 𝑖 for gene 𝑔, which affect the mean 
and variance of gene expressions within batch 𝑖, respectively. The error terms, 𝑔𝑖𝑗, are 
assumed to follow a normal distribution with expected value of zero and variance 𝜎𝑔
2. 




batch effect parameters (𝛾𝑔𝑖  and 𝛿𝑔𝑖) and uses an empirical Bayes procedure to estimate 
these parameters (Johnson et al., 2007). This procedure pools information across genes in 
each batch to shrink the batch effect parameter estimates toward the overall mean of the 
batch effect empirical estimates. These are used to adjust the data for batch effects. This 
approach provides a robust and often more accurate adjustment for the batch effect on 
each gene. 
 Though ComBat has proven successful in many situations, it is limited in several 
aspects. One limitation of the ComBat model is that it adjusts the data for each gene to 
match an overall, or common cross-batch mean, estimated using samples from all 
batches. While this approach is advantageous for cases with small sample size or where 
the batches are of similar caliber and size, this is not the best solution when one batch is 
of superior quality or can be considered a natural “reference”. In addition, the current 
ComBat approach suffers from sample “set bias” (Patil et al., 2015), meaning that if 
samples or batches are added to or removed from the set of samples on hand, the batch 
adjustment must be reapplied, and the adjusted values will be different - even for the 
samples that remained in the dataset in all scenarios. In some cases, the impact of this set 
bias can be significant. For example, consider a biomarker study, where a genomic 
signature is derived in one study batch (training set) and then later applied or validated in 
future samples/batches (test sets) which were not collected at the time of biomarker 
generation. Once the test sets are obtained and combined with the training data using 
ComBat, the post-ComBat training data may change and the biomarker may need to be 




as t-test and F-test, involve calculating data variance. As ComBat adjustment reduces or 
expands the variance for each gene, it will result in a different test statistic, followed by 
an increased or reduced P value. This may cause certain genes to be included or excluded 
from the biomarker list, resulting in a different biomarker from before. If ComBat is 
applied on multiple training/test combinations separately (i.e. say at different times), then 
the derived biomarker may be different between different dataset combinations. 
Therefore, the value of establishing the training set as a “reference batch” to which all 
future batches will be standardized would have a significant impact. This would allow the 
training data and biomarker to be fixed a priori but still enable the application of the 
biomarker on an unlimited set of future validation or clinical cohorts. 
 In addition, ComBat adopts Gaussian distribution assumptions for the data, which 
causes several issues in addressing batch effects on RNA-Seq count data.  
 First, many of the batch effect adjustment methods either do not directly provide 
adjusted data with batch effects removed, or do not preserve the integer nature of counts 
in the adjusted data, despite the requirement of software such as edgeR and DESeq2 that 
specifically require untransformed count matrices as inputs. This results in an 
inconsistency in the analysis pipeline of RNA-Seq studies, as batch corrected data cannot 
be used as inputs for these differential expression software. For this practical issue, it is 
favorable to develop a method which generates adjusted data and is able to preserve the 
count nature of data.  
 More importantly, many popular adjustment methods, including ComBat, assume 




appropriate distributional assumption for counts. These methods typically estimate 
parameters representing differences in the statistical moments across batches (usually the 
mean and the variance). Then they adjust all batches to the same overall level in these 
moments. Such adjustment does not preserve integers, and may results in negative values 
in adjusted count matrix, which is difficult to interpret biologically. In addition, it has 
been well-established that there exists a mean-variance dependence in RNA-Seq count 
data (Law et al., 2014). Distributions of counts are skewed and over-dispersed, i.e. the 
variance is often larger than the mean of gene expression and genes with smaller counts 
tend to have larger variances. These properties cannot be reflected with Gaussian 
distribution, which assumes independent mean and variance parameters. Negative 
binomial regression models have been widely used to model count data in RNA-Seq 
studies. The Negative binomial distribution has the potential to describe the skewness and 
mean-variance relationship observed in count matrices. We propose to extend the original 
ComBat framework to RNA-Seq studies using negative binomial regression. 
 Finally, existing methods may not be flexible enough to address all types of batch 
effects. In particular, including batch variables in software for differential expression may 
be sufficient to account for batch effects in the mean expression. However, since both 
software assume a single dispersion parameter for all samples, variance batch effects is 
restricted, and completely determined by mean batch effects, due to the properties of 
negative binomial modeling. Such assumption is strong and may not always hold for real 





 To address the limitations of ComBat, in the sections below, we first detail the 
modifications for selecting a reference batch, and demonstrate the utility and increased 
efficacy of the reference-batch ComBat. Reference-batch ComBat makes sense in 
situations where one batch or dataset is of better quality or less variable. In addition, this 
approach avoids the negative impacts of test set bias in the generation of the biomarker 
signatures. We then present ComBat-Seq, which extends the original ComBat adjustment 
framework to address the challenges in batch correction in RNA-Seq count data. It 
generates adjusted data in the form of counts, thus preserving the integer nature of data. 
We demonstrate that ComBat-Seq adjustment has potential benefits in differential 
expression compared to the other adjustment methods, especially when there is a large 
variance batch effect in the data. 
Reference-batch ComBat for personalized clinical biomarker development 
The reference-batch ComBat model 
 We present a reference-based batch adjustment approach that uses one batch as 
the baseline for the batch adjustment. The reference batch is not changed and the other 
batches are adjusted to the mean and variance of the reference. Thus, as long as the 
reference batch does not change, the adjustments and adjusted data would be the same, 
regardless of the batches of data that are included in the dataset. This also allows batches 
of data to be adjusted at different times without impacting the results. This approach will 
be advantageous to data generating consortiums where data arrive sequentially in small 
batches. It will also be important for applications in personalized medicine where 




our reference-based version of ComBat, we will assume a model slightly different than 
the current linear model in ComBat, namely: 
𝑦𝑔𝑖𝑗 = 𝛼𝑟𝑔 + 𝑋𝑖𝑗𝛽𝑟𝑔 + 𝛾𝑟𝑔𝑖 + 𝛿𝑟𝑔𝑖 𝑔𝑖𝑗 
where 𝑋𝑖𝑗 and 𝛽𝑟𝑔 are the design matrix and regression coefficients as described before, 
but 𝛼𝑟𝑔 is the average gene expression in the chosen reference batch (𝑟). 
Furthermore, 𝛾𝑟𝑔𝑖  and 𝛿𝑟𝑔𝑖 represent the additive and multiplicative batch differences 
between the reference batch and batch 𝑖 for gene 𝑔. The error terms, 𝑔𝑖𝑗 are assumed to 
follow a Gaussian distribution with expected value of zero and a reference batch variance 
𝜎𝑟𝑔
2 . The empirical Bayes estimates for 𝛾𝑟𝑔𝑖  and 𝛿𝑟𝑔𝑖 will be obtained as in the current 
ComBat approach. 
Dataset descriptions 
Pathway simulation. We generated simulated data to represent a case where we (1) 
derive a gene expression signature of a biological pathway or drug perturbation, and (2) 
profile the signature into another batch of data to predict pathway activity (or drug 
efficacy). The study consists of two experimental batches which are designed as follows: 
batch 1 is given by a 200 (gene) by 6 (sample) matrix of expression data, where the 
columns contain three replicate samples before pathway activation and three after 
activation (i.e. overexpressing key pathway driving genes). Among the 200 genes, the 
first 100 represent signature genes that are differentially expressed (before vs. after) 
based on a before Gaussian distribution:𝑁(0, 0.1), and an after distribution: 𝑁(1, 0.1). 




representing genes that do not respond to the pathway perturbation. Batch 2 consists of a 
200 (gene; same genes as batch 1) by 600 (sample) matrix, and represents a large and 
highly variable patient data set. The 600 patients are divided equally into 6 subgroups 
with different levels of pathway activation between groups. Signature genes are drawn 
from a 𝑁(𝜇, 10) distribution, where 𝜇 = 0.5, 0.7, 0.9, 1.1, 1.3, and 1.5 for the six 
subgroups. The control genes are drawn from a 𝑁(0.5, 10) distribution. We set up these 
simulation studies based on the design of real signature profiling studies (Rahman et al., 
2017), and selected parameters to capture the statistical properties of realistic gene 
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TCGA (733 patients) 
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Up-regulated 
genes 




0.01 0.014 1.596 1.592 1.638 1.697 1.924 2 
Non-
signature 
genes 0.027 0.031 0.523 0.512 0.529 0.575 0.605 0.658 
Table 2.1. Mean and variance of gene expression distributions estimated from the EGFR 
signature and the TCGA breast cancer patient datasets. In TCGA, we used proteomics data of 
the patients, and binned the EGFR protein expression into 6 gradually increasing levels, 
partitioning all patients into 6 equal-sized groups. Mean and variances are estimated within each 
group. Up- and down-regulated genes are both EGFR signature genes derived by ASSIGN. The 
design and parameters for our simulation studies resemble the real estimates in these tables. Batch 
1 represents the EGFR signature dataset with small gene variances, and a clear separation 
between the two condition groups in the expression of up-regulated genes. Batch 2 resembles the 
TCGA patient data with much larger variances than Batch 1. 
Oncogenic signature. The growth factor receptor network (GFRN) contributes to breast 
cancer progression and drug response. This RNA-Seq dataset is designed to develop gene 
signatures for several GFRN pathways: AKT, BAD, HER2, IGF1R, RAF1, KRAS, and 
EGFR. We used recombinant adenoviruses to express these genes in case samples and 
produce green fluorescent protein (GFP) in control samples, using replicates of human 




overexpressing GFRN genes and GFP controls (Rahman et al., 2017). This dataset 
contains 89 samples, which are created in three batches: batch 1 contains 6 replicate 
samples of each for AKT, BAD, IGF1R, and RAF1, 5 replicates for HER2, and 12 
replicates for GFP controls (GEO accession GSE83083); batch 2 consists of 9 replicates 
of each for three types of KRAS mutants and GFP control (GEO accession GSE83083); 
batch 3 contains 6 replicates of each for EGFR and its corresponding control (GEO 
accession GSE59765). We derived signatures from this dataset and predicted pathway 
activities and drug effects in cell line and patient datasets with ASSIGN (Shen et al., 
2015). 
Simulation study 
 We used the simulated data, as described above, to represent a gene expression 
signature study for an activated (or knocked down) biological pathway or drug 
perturbation that is profiled into another batch of data to predict pathway activity (or drug 
efficacy). We used the two versions of ComBat (original and reference) to combine the 
two batches and to enable the prediction of the activity strength of the pathway from 
batch 1 into the batch 2 samples. Batch 1 was selected as reference for the reference-
batch ComBat. Pathway activation levels are added in both versions of ComBat as 
covariates.  
 The original and reference-batch ComBat yield very different results in the two 
batches (Figure 2.1). The original ComBat uses the overall mean and variance of each 
gene across all batches as a background profile. Due to the large sample size and 




variance. As a result, ComBat significantly increased the variance of batch 1 to match the 
variance of batch 2. As illustrated in Figure 2.1, the original ComBat results in a near 
complete loss of signal in batch 1. In comparison, reference-batch ComBat does not 
change the chosen reference (batch 1). It estimates the background means and variances 
based on batch 1, and adjusts batch 2 accordingly. After adjustment, the true signals of 
the pathway are recovered in the second batch. In this setting where batch 1 is of better 
quality, but batch 2 is more variable and larger in size, reference-batch ComBat retrieves 
biological signals of interest more successfully than the original version. We note that the 






Figure 2.1. Simulated pathway datasets before and after batch correction using original and 
reference-batch ComBat. The figure shows the heatmaps of the gene-by-sample expression 
matrices for the two simulated batches. Pathway activation levels are included as covariates in the 
two versions of ComBat. Batch 1 is less variable than batch 2, and is better in quality for 
identifying signatures for the pathway. Using the original ComBat does not remove the variance 
in batch 2. Instead, it causes a severe loss of signal in batch 1 by inflating the variance. 
Reference-batch ComBat does not change the chosen reference (batch 1) and leads to clearer 
signal detection in batch 2.  
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 To quantify the impact of batch correction on batch 1, we use a k-means 
clustering approach to attempt to identify the biomarker gene set (the first 100 genes are 
the signature genes and the subsequent 100 genes are unaffected by the perturbation). We 
treat the gene expression of each sample as high-dimensional vectors (batch 1: 6 samples, 
batch 2: 600 samples). We used k-means clustering to divide these vectors into two 
groups for batch 1 alone, batch 2 alone, and batches 1 and 2 combined, with both 
ComBat adjustments (original and reference). We compared the clustering assignment of 
genes with the signature/non-signature separation, and calculated the accuracy as the 
maximum percentage of correctly classified genes in either way of labeling the two 
clusters as signatures and non-signatures. We evaluated how using original and reference-






Figure 2.2. Cluster assignment of the 200 genes using k-means algorithm, where k=2. Color 
bars show the 200 genes from top to bottom, which corresponds to the gene labels in Fig. 4. The 
red and blue bars represent signature and control genes, respectively. During batch adjustment, 
true activation levels are included as covariates. In the batch adjusted data, we first clustered 
genes into 2 groups without specifying the group sizes or labels. Then, clusters are assigned as 
signature and control by how it best accords with the original separation. a) In batch 1, genes are 
correctly separated. But combining batch 2 with batch 1 without ComBat adjustment changes the 
signature / non-signature separation. Only 58.5% genes remain the same in the combined dataset. 
b) Reference-batch ComBat gives cluster assignment that is more consistent with the true 
separation than original ComBat, in batch 1 only, batch 2 only, and the combined dataset of batch 
1 and 2. These results suggest that the original ComBat breaks the similarity between genes in the 
same group (signature or control), where similarity is measured by the Euclidean distance. Only 
reference-batch ComBat is able to preserve this similarity. 
 In batch 1 without adjustment, all genes are correctly separated into signature and 
non-signature. However, this separation is confounded when batch 2 is combined with 
batch 1, as only 58.5% of the genes are correctly separated in the combined dataset. 
When using original ComBat, because the variance of batch 1 is artificially increased, the 










































accuracy in batch 1 alone drops from 100 to 54.5%, and only 64.5% of the genes 
maintain their correct signature/non-signature labels after combining batch 2 with batch 
1. In contrast, reference-batch ComBat keeps the cluster assignment in the adjusted batch 
1 100% correct, because batch 1 stays intact as the reference, and 91% of the genes retain 
their correct labels in the combined dataset after adjustment. Thus reference ComBat 
improves the ability to identify biomarker genes across multiple studies compared to no 
adjustment and standard ComBat. 
EGFR signature and drug prediction 
 We also considered a real signature study using ASSIGN (Shen et al., 2015), a 
pathway profiling toolkit based on a Bayesian factor analysis approach, to develop an 
EGFR pathway signature from the oncogenic signature dataset. ASSIGN allows for 
derivation of signatures from a pathway perturbation experiment, and adapts signatures 
from experimental datasets to disease. Our goal was to predict EGFR pathway activity in 
two RNA-Seq datasets: a breast cancer cell line panel (Daemen et al., 2013) and from 
breast carcinoma patients in TCGA (Cancer Genome Atlas Network, 2012). As in the 
simulation study, the two RNA-Seq test sets were first combined with the EGFR training 
set separately, to adjust for the batch effect between the training and the test set. ASSIGN 
then trains biomarkers from the adjusted EGFR training set, and makes predictions of 
pathway activity in both of the adjusted test sets. We compared the impact of using three 
versions of ComBat (original, mean-only and reference-batch), as well as frozen SVA 




ComBat version  Common genes 




Drug response in cell lines 
Cell line TCGA Erlotinib GSK1120212 
Original ComBat 20 (40%) 0.316 0.132 0.360 0.401 
Mean-only ComBat 44 (88%) 0.331 -0.042 0.294 0.407 
Reference-batch 
ComBat 
50 (100%) 0.442 0.299 0.415 0.520 
Frozen SVA 50 (100%) 0.115 0.092 -0.09 -0.131 
RUV 40 (80%) 0.287 0.182 0.332 0.145 
Table 2.2. Comparison between five batch correction methods in predicting pathway 
activity and drug efficacy. We combined the oncogenic signature dataset with the cell line and 
TCGA patient data separately to adjust for batch effect and enable the profiling of EGFR 
signatures from the oncogenic data to the test sets. We observed the set bias using original 
ComBat (40% same signature genes), mean-only ComBat (88% same genes), and RUV (80% 
same genes) to combine the datasets. Reference-batch ComBat and frozen SVA kept the same 
signature genes. Also, using reference-batch ComBat gave the highest correlations of prediction 
scores with both protein expression and drug response, among all five batch correction methods. 
These results support the benefit of using reference-batch ComBat in this context. 
 We used ASSIGN to develop a 50-gene signature from the EGFR samples in the 
training set (Rahman et al., 2017). We first focus on the three versions of ComBat in the 
ability to generate replicable signatures. Because of the set bias caused by using original 
ComBat, only 20 (40%) of the signature genes are the same between the signatures 
developed in the training set adjusted against the cell line test set compared to the training 
set adjusted against the patient data. The same analysis performed with mean-only 
ComBat produced gene signatures with 44 (88%) of the genes shared between the two 
datasets. Because reference-batch ComBat does not change the EGFR dataset, the 
signatures are identical after (separate) adjustment with the two test sets. This points to 




projected into multiple datasets, even at different times and without the need to combine 
all the data together. 
 We further compared the correlations of pathway predictions with the following 
validation datasets: (1) EGFR protein expression data (cell line and TCGA), and (2) 
EGFR inhibitor drug response (cell lines). As shown in Table 2.2, the correlations with 
protein expression for the reference-batch ComBat adjusted data (Cell Line: 0.442, 
TCGA: 0.299) are the highest in both test sets among all five methods. The correlations 
with drug response are also the highest when adjusting the data with reference-batch 
ComBat. For example, reference adjusted data yield a correlation of 0.415 with Erlotinib 
response and 0.520 with GSK1120212 response, compared to using the original 
(Erlotinib: 0.360, GSK: 0.401) and mean-only (Erlotinib: 0.294, GSK: 0.407) ComBat, 
frozen SVA (Erlotinib: -0.09, GSK: -0.131), and RUV (Erlotinib: 0.332, GSK: 0.145). 
These results strongly justify the benefits of the reference version of ComBat in pathway 
profiling and predicting drug efficacy. 
Discussion 
 Combining multiple genomic datasets is beneficial for boosting statistical power 
of studies, especially in cases where data are generated in small batches necessitated by 
high experimental cost or difficulties in collecting samples. In addition, combining 
batches of data from similar experiments from different labs also provides opportunities 
for increased power for the detection of biological differences, as well as providing ways 
for testing/validating biomarkers generated in one batch of data. The presence of batch 




platforms, protocols, or other factors can often confound the biological signals in data, 
which reduces the benefit of combining datasets. Despite the many previously developed 
techniques for batch adjustment, there are still situations where new methods need to be 
developed to appropriately or more effectively remove batch effects. 
 We illustrated the benefits of selecting a reference batch in batch correction, in 
situations when one batch is high quality and less variable, and when biomarkers need to 
be developed from one study, fixed and validated on another study. Particularly in the 
situation where the goal is to generate fixed biomarkers, including an extra batch of data 
to those in hand can strongly affect the results, an issue described as “set bias”. In these 
situations, analysis need to be re-run in order to process the new batch of data, which can 
cause the biomarker genes to be largely different. 
 Our reference-batch ComBat is proven more successful in retrieving biological 
signals in signature profiling examples, where one batch shows a clear signal of 
biological conditions. We demonstrated that reference-batch ComBat resolves the “set 
bias” caused by the original version of ComBat in adding data sequentially, and yields 
better prediction of pathway activities and drug effects. Although this approach is only an 
alternative expression of the ComBat model, its implementation has critical impact in real 
batch correction scenarios. 
Availability 
 The reference-batch ComBat has been integrated into the ComBat function 
available in the “sva” Bioconductor package (Leek et al., 2012). Specifically, ComBat 




batch name or number to be used as the reference batch. Code for the simulation dataset 
is available on https://github.com/zhangyuqing/meanonly_reference_combat. 
ComBat-Seq: batch effect adjustment for RNA-Seq count data 
Using appropriate model assumptions for RNA-Seq count data 
 Many existing methods for batch effect adjustment, including ComBat, assume 
continuous, bell-shaped Gaussian distributions for data. However, in RNA-Seq studies 
where data are skewed, over-dispersed counts, this assumption is not appropriate and may 
lead to erroneous results. An example demonstrating the weakness of Gaussian-based 
models is given in Figure 2.3. In this example, we simulated a count matrix using 
polyester (Frazee et al., 2015) with balanced case/control design and 2 batches. Figure 
2.3 shows the counts in a gene. The control samples in both batches have low expression, 
while there is a case sample in batch 2 with a relatively large count over 30. When 
estimating the differences in mean across batch, due to the sample with the large count in 
the second batch, the mean of the second batch is estimated to be larger than that of batch 
1. If we apply Gaussian-based batch adjustment which brings the mean to the same level, 
control samples in the second batch will be adjusted to negative values, while counts in 
the first batch will be increased. This results in a significant artificial difference between 
control samples from the two batch after correction (P = 0.0033). These observations 
demonstrate the potential issue of applying batch correction method using Gaussian 






Figure 2.3. Problematic results caused by applying Gaussian-based batch adjustment 
approach on count data. We simulated count matrix with a balanced case-control design and 2 
batches. The figure shows counts in a gene which is lowly expressed in almost all control 
samples. However, one case sample in the second batch contains a high count. Adjustment based 
on Gaussian distribution brings the mean of two batches to the same level, causing artificially 
induced differences across control samples from the two batches. When applying ComBat-Seq 
which is based on negative binomial distributions, the adjusted data no longer contain the 
negative values or the erroneous significant difference between control samples from the two 
batches. 
 We then applied our ComBat-Seq method, which assumes negative binomial 
distributions for the underlying data. As shown in Figure 2.3, the adjusted data do not 
contain negative values or a false significant difference between the control samples of 
the two batches. This suggests that the negative binomial assumption indeed addresses 
the limitations mentioned above. Below we detail the methods of ComBat-Seq, and 
further evaluate its performance and utilities. 
ComBat-Seq framework 
 We propose a negative binomial regression model to estimate batch effects based 
on the count matrix in RNA-Seq studies. With the estimated batch effect parameters, we 
calculate “batch-free” distributions, i.e. the expected distributions if there were no batch 




distributions of data to the batch-free distributions. Below we further describe the details 
of this method. 
 We define a regression model for each gene. Let the expression count value for 
gene 𝑔 of sample 𝑗 from batch 𝑖 be denoted by 𝑦𝑔𝑖𝑗. We assume that 𝑦𝑔𝑖𝑗 follows a 
negative binomial distribution 𝑁𝐵(𝜇𝑔𝑖𝑗 , 𝜙𝑔𝑖), where 𝜇𝑔𝑖𝑗  and 𝜙𝑔𝑖 are the mean and the 
dispersion parameters. We propose the gene-wise model: 
log 𝜇𝑔𝑖𝑗 = 𝛼𝑔 + 𝑋𝑗𝛽𝑔 + 𝛾𝑔𝑖 + log 𝑁𝑗  
𝑣𝑎𝑟(𝑦𝑔𝑖𝑗) = 𝜇𝑔𝑖𝑗 + 𝜙𝑔𝑖𝜇𝑔𝑖𝑗
2  
where 𝛼𝑔 denotes the logarithm of expected counts for “negative” samples. 𝑋𝑗𝛽𝑔 reflects 
changes to the log of expected counts due to biological conditions, which is preserved in 
the data after adjustment. In this term, 𝑋𝑗 may be an indicator of the biological condition 
for sample 𝑗, or a continuous value for a clinical covariate. 𝛽𝑔 denotes the corresponding 
regression coefficient. 𝑁𝑗 represents the library size, i.e. total counts across all genes in 
sample 𝑗. The mean and dispersion batch effect parameters are denoted by 𝛾𝑔𝑖 and 𝜙𝑔𝑖, 
respectively, modeling the effect of batch 𝑖 on gene 𝑔. We estimate the model 
parameters, especially batch effect parameters 𝛾𝑔𝑖  and 𝜙𝑔𝑖, following the established 
methods in edgeR (Robinson et al., 2010, McCarthy et al., 2012, Chen et al., 2014). 
Specifically, the mean batch effect parameters 𝛾𝑔𝑖s are estimated with Fisher scoring 
iteration, implemented in an optimized way to reduce the computational time. The 
dispersion parameters 𝜙𝑔𝑖s are estimated gene-wise by maximizing the Cox-Reid 




dispersion estimates. The estimates for mean of expression are not required to be non-
negative, since they are on the log scale. We estimated the gene-wise dispersion within 
each batch in ComBat-Seq. 
 After the modeling, we obtain estimated batch effect parameters ?̂?𝑔𝑖  and ?̂?𝑔𝑖, as 
well as the fitted expectation of count ?̂?𝑔𝑖𝑗. We then calculate parameters for “batch-free” 
distributions as follows: we assume that the adjusted data 𝑦𝑔𝑗
∗  follows a “batch-free” 
negative binomial distribution 𝑁𝐵(𝜇𝑔𝑗
∗ , 𝜙𝑔
∗ ), where parameters are calculated as 
log 𝜇𝑔𝑗









Then, the adjusted data 𝑦𝑔𝑗
∗  is calculated by finding the closest quantile on the batch-free 
distribution to the quantile of the original data 𝑦𝑔𝑖𝑗 on the empirical distribution, 
estimated as 𝑁𝐵(?̂?𝑔𝑖𝑗 , ?̂?𝑔𝑖),. Specifically, we find the adjusted value 𝑦𝑔𝑗
∗  such that 
𝐹∗(𝑦𝑔𝑗
∗ ) = 𝑃(𝑦∗ ≤ 𝑦𝑔𝑗
∗ ) is closest in absolute value to 𝐹(𝑦𝑔𝑖𝑗) = 𝑃(𝑦 ≤ 𝑦𝑔𝑖𝑗). Zero 
counts are mapped to zeros. We perform this mapping for every value in the count 






Figure 2.4: A diagram for the ComBat-Seq modeling and adjustment workflow. ComBat-
Seq first fits a negative binomial regression to counts of each gene, then estimate parameters 
representing batch effects in the model using established methods from edgeR. It then calculates 
the expected distribution of data if there were no batch effects, and adjust the data by mapping the 
quantiles from the data to the “batch-free” distributions. 
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 We evaluated the performance of ComBat-Seq with simulation experiments 
consisting of three steps: we 1) simulated RNA-Seq studies with biological conditions 
and batch effects, 2) adjusted the batch differences with ComBat-Seq as well as other 
available methods, and 3) evaluated the performance of batch effect adjustment by the 
impact on differential expression using the adjusted data. 
 We used the polyester R package (Frazee et al., 2015) to simulate realistic RNA-
Seq studies, which are in the form of gene-by-sample count matrices. We designed two 
biological conditions and two batches of samples. The polyester package human genome 
reference example provides information for 918 genes, which we divided into two 
groups: group 1 has higher expression in batch 2 and lower in batch 1, while group 2 has 
the reversed pattern, higher in batch 1 and lower in batch 2. This forms a batch effect in 
the “composition” of expression, which cannot be fully addressed by normalization. We 
assume a biological variable with two levels, “negative (0)” and “positive (1)”, which can 
represent “control” and “tumor” samples in a real dataset, for example. We simulated 
both up-regulated and down-regulated true differentially expressed genes in both gene 
groups with increased expression in the positive (up-regulated) or the negative (down-
regulated) biological condition. The remaining genes are only affected by batch, not by 
the condition. Differences in the average count of genes are simulated by specifying fold 
changes across biological and batch sample groups using polyester. We also made the 




true dispersion parameters across batches. Figure 2.5 shows the design we used for 
simulated data. 
 
Figure 2.5: Study design of the simulation experiments. The data are in the form of gene by 
sample matrices. We simulated 2 biological conditions: negative (0) and positive (1), as well as 2 
batches. We also simulated 2 groups of genes. Group 1 has higher expression in batch 2 and 
lower in batch 1, while group 2 has the reversed pattern, higher in batch 1 and lower in batch 2. 
The figure shows high expression in yellow, and low expression in blue. We also simulated 
differentially expressed genes in both groups. A deeper color represents increased expression due 
to biological condition. 
 We repeated the simulation while varying the level of mean and dispersion batch 
differences. Specifically, we changed the parameters for simulation such that mean of batch 
2 is 1.5, 2, or 3 times that of batch 1. The dispersion of batch 2 was set to be 2, 3 or 4 fold 
of that of batch 1. Experiments with no mean batch effect or no dispersion differences were 
also included. Results were averaged over 300 repeated simulations under each parameter 
setting.  
 Our selected parameters in simulations are consistent with the degree of batch 
effect in real data, as summarized in Table 2.3. Our observed condition signal (fold 
change in expression) from real studies range from 1.65 to 3.98, and we specified a 
biological signal of 2 fold in simulations. With regard to batch differences in the 




variance difference to be in 1.26 to 7.09 fold. Our selected parameters in the simulations 
align with the realistic range, suggesting that the results are likely representative for the 
expected effect on real data batch adjustment. 
 The batch effects in mean and dispersion (variance) were adjusted with ComBat-
Seq, the “one-step” approach, i.e. to include the batch variable in differential expression 
linear models, as well as with SVA-Seq and RUV-Seq. We also included another 
commonly used method in practice, which is to transform the count matrix to logCPM, 
then use the batch correction methods designed for Gaussian distributed data, such as the 
original ComBat method. Aside from batch adjusted data, we included two additional 
experiments for comparison: differential expression performed on 1) data without 
simulated batch effects, and 2) data with simulated batch differences, but no adjustment. 
We compared both the statistical power (true positive rate, TPR) and control of type- I 
errors (false positive rate, FPR) in detection using data without batch effects, data with 
batch effects before and after different adjustments. 
Dataset Condition Batch Mean Batch Dispersion References 
GFRN 1.65 1.88 2.78 Rahman et al., 2017 
CHD8 2.92 1.68 7.09 Sugathan et al., 2014 
TB 3.98 1.62 1.26 Zak et al., 2016, Suliman et al., 2018 
Table 2.3. Levels of biological and batch effects in real datasets. For the condition effect, we 
used edgeR to perform differential expression within one of the batches in the studies, and 
identified the top-50 up-regulated, and top-50 down-regulated genes, ranked by FDR corrected P 
values. We took the median of fold changes across conditions among the top-50 up-regulated 
genes, and the median of those among the down-regulated genes. We reported the maximum of 
two medians in the table. For mean batch effects, we calculated the gene-wise average expression 
within each batch, and each biological condition. We took the median of mean expression across 
genes, then compared the medians across batch, and report the maximum fold change. For 
dispersion differences, we report the maximum fold change in the median gene-wise dispersion 




 Results comparing all batch adjustment methods under different settings of degree 
of batch effects are summarized in Figure 2.6. Introducing batch effects reduces both true 
and false positive rates. For example, having only batch effects in the mean of at 1.5 fold 
but no dispersion differences reduces FPR to 0.028, and TPR to 0.94, compared to data 
without batch effects (FPR: 0.048, TPR: 0.96). A larger difference in the mean or 
dispersion leads to a larger decrease in the power of detection in the unadjusted data. For 
instance, data with only mean batch effect but at a 3-fold difference have a 0.64 TPR, and 
data with no mean batch effect but a 4-fold dispersion effect have a 0.66 TPR. All 
evaluated methods are able to improve power for detection after adjusting the data with 
batch effects, and such benefits increase when the degree of batch differences becomes 
more severe. Among the batch correction methods considered, ComBat-Seq generally 
achieves the highest true positive rates. With a 1.5-fold mean and a 2-fold dispersion 
batch effect, we observed a 0.89 TPR from ComBat-Seq, which is higher than the other 






Figure 2.6: Simulation results under increasing level of differences across batch in the mean 
and variance of expression. Batch effects in the mean or the variance will cause a loss of power 
for differential expression detection. All available methods are able to increase the power for 
analysis, and ComBat-Seq generally achieves the best power. Also, when there are high levels of 





 In addition, when there are large dispersion differences across batch, ComBat-Seq 
is able to better control false positive rates. When applied on data with no mean batch 
effect and a 3-fold dispersion differences, ComBat-Seq generates the smallest FPR of 
0.039 among all methods (including batch as a covariate: 0.043, original ComBat on 
logCPM: 0.046, RUV-Seq: 0.044, SVA-Seq: 0.049). The false positive rates using data 
adjusted by ComBat-Seq further decrease as differences between dispersion increase 
(0.031 at the 4-fold dispersion difference, compared to the 0.039 FPR at the 3-fold 
difference). This suggests that ComBat-Seq is better at handling variance batch effect in 
the data compared to the other available methods. 
 When there is no dispersion difference across batch, ComBat-Seq yields higher 
false positive rates with no further gain in detection power. For example, when data 
contain no dispersion batch effect, only a 2-fold mean batch effect, ComBat-Seq, SVA-
Seq, and including batch as a covariate in the differential expression model all achieve 
0.97 TPR, while ComBat-Seq has the highest FPR of 0.059 (0.047 for both the other two 
methods). This is consistent with the intuition for batch correction. Existing methods, 
such as including batch as a covariate in the differential expression methods, may be 
sufficient in addressing batch effect in the mean. In this case, ComBat-Seq which 
assumes separate dispersion across batch may be redundant and lead to higher false 
positives. Only when there exist dispersion/variance differences in the data are methods 
which specify separate dispersion parameters necessary. 
 We also compared ComBat-Seq with the commonly applied approach to 




Gaussian distributions. This method essentially assumes a log-normal distribution for the 
data. In simulations, we observed that ComBat-Seq generally out-performs log 
transforming the data in terms of power and control of false positives. These results 
provide evidence that using appropriate probabilistic models for count data may be more 
beneficial than arbitrarily transforming the data. 
Application to the GFRN pathway signature dataset 
 We applied ComBat-Seq to address batch effects in an RNA-Seq dataset from a 
perturbation experiment using primary breast tissue attempting to profile the activity 
levels of growth factor receptor network (GFRN) pathways in relation to breast cancer 
progression (Rahman et al., 2017, McQuerry et al., 2019). We took a subset of 
experiments, which consists of 3 batches. In each batch, the expression of a specific 
GFRN oncogene was induced by transfection to activate the downstream pathway signals 
(different oncogene/pathway in each batch). Controls were transfected with a vector that 
expresses a green fluorescent protein (GFP), and GFP controls were present in all 
batches. More specifically, batch 1 contains 5 replicates of cells overexpressing HER2, 
and 12 replicates for GFP controls (GEO accession GSE83083); batch 2 contains 6 
replicates of each for EGFR and its corresponding controls (GEO accession GSE59765); 
batch 3 consists of 9 replicates of each for wild type KRAS and GFP controls (GEO 
accession GSE83083). This is a challenging study design for batch effect adjustment: the 
control samples are balanced across batches, while each of the 3 kinds of treated cells, 




favorable adjustment would pool control samples from the three batches, while keeping 
all treated cells separated from the controls and from each other. 
 Among the batch correction methods considered, only RUV-Seq, the original 
ComBat used on logCPM, and ComBat-Seq output adjusted data. We apply these 
methods to address the batch effects in this dataset. We compared ComBat-Seq with the 
other methods, both qualitatively through principal component analysis (PCA), and 
quantitatively with explained variations by condition and batch. 
 Figure 2.7 shows the scatter plot of samples projected on the first two principal 
components in the unadjusted data, and in data adjusted by RUV-Seq, ComBat-Seq, and 
using ComBat on logCPM. We observed a strong batch effect in the unadjusted data, 
which was not fully addressed by RUV-Seq. In the PCA of ComBat-Seq adjusted data, 
we observe the pattern expected if there were no batch effects, with GFP controls 
clustered together, and treated samples from three conditions are scattered at different 
locations. The effective adjustment of ComBat-Seq is further shown in the boxplot of 
proportion of explained variation by biological condition and batch across genes. In 
ComBat-Seq adjusted data, variation of gene expression explained by batch is greatly 
reduced compared to that in the unadjusted data. These results suggest a successful 





Figure 2.7: Application of ComBat-Seq for removing batch effects in a pathway activation 
dataset. The unadjusted data contains a strong batch effect, as samples clearly separated by batch 
in the principal components (top left panel, “Unadjusted”). An effective adjustment is expected to 
bring control samples from the 3 batches to the same level, while maintaining biological signals 
from the different treated samples, each of which is only present in a single batch. We observed 
that in the PCA plots (left panel), ComBat-Seq is able to recover the expected biological pattern, 
while RUV-Seq was not able to fully address the batch effect. This is further shown in the 
analysis of explained variation (right panel) in unadjusted data, and in data adjusted by ComBat-




 Finally, though ComBat-Seq does not show clearly improved results compared to 
ComBat used on logCPM, we emphasize its increased statistical power in differential 
expression, as we have shown in the simulation studies. 
Parameter estimation with shrinkage 
 Genomic data often have small sample sizes, which makes it challenging to 
estimate the parameters in the ComBat-Seq model. One of the advantageous features of 
ComBat is the hierarchical empirical Bayes modeling, which pools information across 
genes for parameter estimation, making the estimates more robust for data with small 
sample sizes and/or outlying values (Johnson et al., 2007). Similar methods for 
estimation with small sample size have been proposed for negative binomial regression 
models used on count data. The edgeR software uses a similar idea in its model, which is 
to estimate the dispersion parameter by maximizing a weighted likelihood, combining 
both gene-wise likelihood, and likelihood assuming universal dispersion across genes 
(Chen et al., 2014). 
 In ComBat-Seq, we include a similar option to estimate parameters, which is 
inspired by the non-parametric empirical Bayes method in ComBat. In the ComBat-Seq 
function, users may select to use this alternative approach by setting the “shrink” 
parameter to TRUE (default FALSE). 
 After obtaining the batch effect parameters ?̂?𝑔𝑖  and ?̂?𝑔𝑖, we adjust these parameters 














where the weights are defined as 




𝑑 represents the density function for negative binomial distributions. These formulae are 
directly adopted from those for the posterior estimates of mean and variance batch effect 
parameters in ComBat. Parameters will be estimated with the gene-wise estimates from 
all the other genes aside from itself. Estimates with a larger likelihood for the data will be 
assigned a higher weight. We then calculate the “batch-free” distribution, using the 
estimates as defined above. Adjusted data are generated the same as before. 
 We evaluated this approach on the GFRN pathway signature dataset, using only 
the control samples from the three batches. Expected adjustment should pool all samples 
together. We observed that applying shrinkage to the parameter estimates tends to result 
in under-estimated batch effects, which leads to an under-correction of the data. Batch 





Figure 2.8 Comparison between estimation with and without shrinkage. We applied the 
ComBat-Seq model both with and without shrinkage on the GFRN pathway signature dataset, 
using only the control samples. When shrinkage is used, the estimated mean batch effect 
parameters of all genes tend to have a more concentrated distribution, centered at zero. This 
suggests that the mean batch effects are estimated to be closer to zero, an under-estimation 
compared to the results using ComBat-Seq without shrinkage. The under-estimation of batch 
effects leads to an under-correction, as shown in the PCA plots. Samples are still clearly 




 We would like to point out, however, that our proposed model is a heuristic 
extension of the ComBat non-parametric estimation approach. Deriving an empirical 
Bayesian approach with negative binomial distributed count data is challenging, for there 
are no conjugate distributions available. A full Bayesian approach may be feasible, but 
requires complicated computation and is beyond the scope of our work. Further 
exploration on the impact of outlying counts in RNA-Seq data, and the benefits of 
shrinkage in batch effect estimation and adjustment is needed. 
Discussion 
 In simulations, we observed that when there is no true difference in dispersion 
across batch, applying ComBat-Seq, which specifies different dispersion parameters for 
batches, results in increased false positive rates compared to the other methods without 
further increasing the detection power. ComBat-Seq controls false positives and shows 
benefits in increased true positive rates only when a true dispersion batch effect is present 
in the data. This is consistent with the intuition of batch effect adjustment, that modifying 
the data in any way comes with a risk of jeopardizing biological signals in the data. 
Therefore, batch effects should only be adjusted when they are present and result in 
unfavorable impact on downstream analysis. Such observations emphasize the 
importance for careful diagnosis of batch effect before applying any transformation to the 
data. 
 Our study has several limitations. First, we used an idealized data model in 
simulations, and characterized mean and dispersion batch effects in the form of fold 




assumption for the data especially for the differential expression task, and it is easy to 
implement with the polyester package. However, distributions across batches may also 
differ in higher-order moments (e.g. skewness, kurtosis). And therefore, there may be 
other methods to model count data affected by batch effects, which would be interesting 
to explore in future research. Second, we focused primarily on addressing the unwanted 
impact of batch effect on downstream differential expression. It is known that batch 
effects may also negatively impact other biological tasks, such as developing predictive 
models. Performance of batch correction in these tasks requires further evaluation, but is 
beyond the scope of this work. Third, due to space limitations, we provided only a single 
application example. More examples would be desirable to demonstrate the utilities of 
ComBat-Seq. And finally, our ComBat-Seq method, similar to any other batch 
adjustment methods, will not work well on data with severely or even completely 
confounded study designs. Careful experimental design has been widely advised to 
mitigate the unfavorable impact of batch effects. 
Availability 
 Same as ComBat, we aim to distribute ComBat-Seq in the open source 
Bioconductor package sva (Leek et al., 2012). Currently, ComBat-Seq is included as a 
function in a development version of sva, available at https://github.com/zhangyuqing/sva-
devel. Instructions for using ComBat-Seq, and code to reproduce the results are available 
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Chapter 3. The impact of sources of heterogeneity on loss of accuracy from genomic 
prediction models 
This chapter was originally published in the following manuscript: 
Zhang, Y., Bernau, C., Parmigiani, G., and Waldron, L. (2018). The impact of different 
sources of heterogeneity on loss of accuracy from genomic prediction models. 
Biostatistics (Oxford, England). DOI: 10.1093/biostatistics/kxy044 
Introduction 
 Quantification of heterogeneity between studies and its impact on validation of 
decision models is important across a wide range of applications. It has been noted that 
independent validation of genomic classifiers is rare (Castaldi et al., 2011), and the 
difficulty of external validation and study heterogeneity is common not only in 
microarray studies but in GWAS (König, 2011), and RNA-Seq studies (Xu et al., 2016). 
External validation is critical in any research domain affected by heterogeneous samples, 
sample selection bias, or technical batch effects. However, it has proven especially 
difficult for classifiers and subtypes identified from gene expression data. Patient 
populations can be heterogeneous in their exposures, geography, race/ethnicity, and 
socioeconomic status, and these differences could manifest as biologically distinct forms 
of diseases that vary systematically between studies. Batch effects (Leek et al., 2010) and 
platform effects impact on reproducibility across studies. The sources of batch variation, 
sampling bias, and other heterogeneity may be unknown. Finally, “samples of 
convenience” are the norm in translational genomics research (Simon et al., 2009), due to 




follow-up. In spite of these challenges, we expect clinically-relevant genomic findings to 
be reproducible at hospitals with different populations around the world, suggesting 
robustness in the presence of some heterogeneity. The “molecular portraits” of breast 
cancer, for example, have been broadly reproduced across platforms and centers (Hu et 
al., 2006). 
 Previous studies have shown that accuracy estimates of genomic prediction 
models based on independent validation are inferior to cross-validation estimates 
(Castaldi et al., 2011, Bernau et al., 2014), but did not identify the sources of 
heterogeneity responsible. It was shown (Ma et al., 2014, Chang and Geman, 2015), by 
learning diagnostic models on a large number of studies, how to estimate whether enough 
heterogeneity has been explored to achieve a desired degree of generalizability. 
Specifically, it was shown that cross-study validation (CSV) error rate exceeds the 
randomized cross-validation (RCV) error rate for any number of studies (Chang and 
Geman, 2015). The latter increases with the diversity of studies, and both converge to the 
optimal rate for the whole population. Methods for correction of validation accuracy 
estimation in training samples of biased covariate distribution to the unbiased distribution 
(Cortes et al., 2008) and to the covariate distribution in test samples (Uno and Inoue, 
2017) have been proposed. 
 It remains critical to understand the contributions of each component of “study 
effects” to the difference of performance. In practice, a standard approach is to remove as 
many sources of heterogeneity as possible, such as limiting meta-analyses to late-stage, 




recommendations for the replication of genome-wide association studies include studying 
a “similar” population. However, in many cases it is unclear what measures of study 
similarity are important, and unnecessarily restrictive inclusion criteria have costs in 
reduced sample size and loss of generality of findings. Thus the question arises of which 
sources of heterogeneity do in fact impact the accuracy of cross-study prediction, and 
how these can be determined from the data. We propose that the impact even of still-
unidentified sources of heterogeneity can be accounted for and quantified if independent 
studies are available. 
 We compare within and across study validation of omics-based prediction models 
using simulations which are generated from publicly available datasets, including both 
microarray and sequencing data. We investigate the impact of three possible types of 
heterogeneity on cross-study validation performance: changes in prevalence of known 
clinical and pathologic factors, changes in gene expression covariance structure for 
example due to batch or platform effects, and changes in the true models associating gene 
expression and clinical factors with outcome. These sources of heterogeneity are 
manipulated and equalized in turn, while we compare within- to across-study validation 
of predictions for the disease outcome or risk scores for survival. The methodology of 
this study can be applied to investigating the effects of study heterogeneity on model 





Materials and methods 
 We evaluate the effects of across-study heterogeneity by resampling of studies, 
and preserving the distribution and covariance of gene expression through resampling of 
individuals within studies. We generate linear models associating clinical/pathological 
variables and gene expression to the outcome based on the original experimental data. 
We use these models to generate new outcome variables, which preserve the properties of 
the original outcome. We emphasize that standard clinical factors were included as 
required, unpenalized covariates in the “true” prognostic model so that their associations 
with outcome would be guaranteed to be preserved across simulations. We review the 
simulation procedure in the following sections, which involves a three-step bootstrap 
method. 
Datasets 
 Public experimental studies are hereafter referred to as the “original” datasets. 
Steps for preprocessing these datasets are detailed in Appendix A. 
Microarray studies. The first compendium consists of 7 curated breast cancer datasets 
(Haibe-Kains et al., 2012, Bernau et al., 2014). Sample information and distributions of 
covariates are summarized in Table 3.1. These studies contain censored disease and 
metastasis-free survival (DMFS) response, and 1021 estrogen-receptor positive breast 
cancer individuals. Available covariates in these studies include patient age at diagnosis, 
tumor size, and histological grade. Age and tumor size were dichotomized at 50 years and 
2cm, respectively (Haibe-Kains et al., 2012), and grade was kept at three levels 




tumor size, grade and patient age are 1.96, 1.65 and 1.2 (Table 3.2). This is consistent 
with commonly used prognostic factors for primary breast cancer such as the Nottingham 
Prognostic Index (Haybittle et al., 1982), showing that the dichotomized tumor size and 
grade are prognostic. 









CAL 68 63.2 57.4 35.3 7.4 61.8 Chin et al., 2016 
MNZ 162 40.7 9.9 73.5 16.7 76.5 Schmidt et al., 2008 
TAM1 317 58.0 18.3 58.4 23.3 91.2 Foekens et al., 2006 
TAM2 128 53.1 31.3 44.5 24.2 93.0 Symmans et al., 2010 
TRB 132 43.2 26.5 51.5 22.0 29.5 Desmedt et al., 2007 
UNT 72 38.9 16.7 43.1 40.3 59.7 Sotiriou et al., 2006 
VDX 142 2.8 71.8 25.4 2.8 57.7 Minn et al., 2007 
Overall 1021 44.1 29.6 50.9 19.5 72.3  
Table 3.1. Covariate distributions in the ER-positive breast cancer microarray datasets. 
Percentages are rounded to the nearest tenth. Datasets acronyms: CAL = University of California, 
San Francisco and the California Pacific Medical Center (United States), MNZ = Mainz hospital 
(Germany), TAM1 and TAM2 represents SUPERTAM_HGU133A and 
SUPERTAM_HGU133PLUS2 (Haibe-Kains et al., 2012), TRB = TransBIG consortium dataset 
(Europe), UNT = the cohort of untreated patients from the Oxford Radcliffe Hospital (United 
Kingdom), VDX = Veridex (the Netherlands). Column labels: #Patients = the number of patients 
after cleaning. %>2cm = percentage of patients in cleaned datasets with tumor size larger than 
2cm. %low, medium and high-grade = percentage of patients with low, intermediate and high 
level of histological grade. %>50yrs = percentage of patients older than 50 years. 
Covariates HR Confidence Interval #Datasets 
Size 1.96 (1.46, 2.62) 7 
Age 1.2 (0.86, 1.65) 6 
Histological Grade 1.65 (1.24, 2.19) 7 
Table 3.2. Synthesized hazard ratios of all covariates in the breast cancer datasets. The 
three-level histological grade is dichotomized for the calculation of HR, by combining the low 
and intermediate levels as 0, and treating the high level as 1. Row labels: Covariates = covariate 
names, HR = hazard ratio synthesized across all base datasets by fixed-effects meta-analysis. 
Interval = 95% Confidence Interval, #Datasets = Number of studies available for hazard ratio. 
Tumor size and histological grade, but not age dichotomized at 50 years, are significantly 




 The other collection, of 5 microarray datasets containing 935 ovarian cancer 
patients (Ganzfried et al., 2013) is available from the curatedOvarianData Bioconductor 
package. Patients with late-stage, high-grade cancer were included. The datasets contain 
patient age and debulking status as available covariates. Age was dichotomized at 70 
years. Distributions of these covariates are summarized in Table 3.3. Synthesized hazard 
ratios of these covariates are 1.84 (age) and 1.48 (debulking), as shown in Table 3.4.  
Name #Patients %>70 years %Suboptimal References 
E.MTAB.386 124 29.8 22.6 Bentink et al., 2012 
GSE26712 182 24.7 51.1 Bonome et al., 2008 
GSE49997 136 14.7 31.6 Pils et al., 2012 
GSE9891 124 19.4 42.7 Tothill et al., 2008 
TCGA 369 23.3 27.6 Cancer Genome Atlas 
Network, 2012 
Overall 935 22.7 34.1  
Table 3.3. Covariate distributions in the ovarian cancer microarray datasets. Column labels: 
#Patients = the number of patients after cleaning. %>70yrs = percentage of patients older than 70 
years. %suboptimal = percentage of patients in cleaned datasets with sub-optimally debulked 
tumors, as opposed to the optimally debulked ones. 
Covariates HR Confidence Interval #Datasets 
Age 1.84 (1.51, 2.24) 5 
Debulking 1.48 (1.23, 1.78) 5 
Table 3.4. Synthesized hazard ratios of all covariates in the ovarian cancer datasets. Row 
labels: Covariates = covariate names, HR = hazard ratio synthesized across all datasets by fixed-
effects meta-analysis. Interval = 95% Confidence Interval, #Datasets = Number of studies 
available for hazard ratio. Both factors are significantly associated with survival. 
The RNA-Seq study. In addition to the microarray studies, we created simulations in 
RNA-Seq data with time-to-event outcome. Lacking sufficient RNA-Seq studies for a full 
cross-study validation, we substituted the TCGA microarray dataset with TCGA RNA-
Seq data in the ovarian cancer study collection. The TCGA RNA-Seq study is also 




microarray cohort. We used the same clinical covariates, patient age and debulking 
status, for the simulations using the RNA-Seq study. 
Metagenomics studies. We further evaluated the impact of heterogeneity in whole-
metagenome shotgun sequencing studies with binary disease outcomes, which are 
available from the curatedMetagenomicData Bioconductor package (Pasolli et al., 2017). 
We focused on 3 studies with gut microbiome samples of type-II diabetes (T2D) patients 
and healthy individuals. The binary outcome indicates the disease status for each sample. 
We identified Body Mass Index (BMI) as the covariate to be balanced for these studies. 
 For predictors we used gene families, as estimated by HUMAnN2 (Abubucker et 
al., 2012) and provided by curatedMetagenomicData, in the prediction models. We 
performed a series of feature selection steps (Appendix A), after which 800 features were 
included in the studies. We dichotomized BMI at 25 based on the empirical separation of 
BMI as “under to normal weight” and “overweight to obese”. Table 3.5 summarizes the 
sample and covariate information of these studies. 
Name #Samples #T2D #BMI >= 25 References 
QinJ stageI 145 71 44.8 Qin et al., 2012 
QinJ stageII 185 90 32.4 Qin et al., 2012 
KarlssonFH 96 53 66.7 Karlsson et al., 2013 
Table 3.5. Sample information and covariate distributions in the whole-metagenome 
shotgun microbiome studies. #Samples: number of samples in each study. #T2D: number of 
type-II diabetes patients. % BMI>=25: percentage of individuals with Body Mass Index (BMI) 
over 25, which suggests that they are overweight or obese. 
Simulation approach and the simulatorZ Bioconductor package 
 We followed an established systematic approach for synthesizing a group of 




prediction methods (Bernau et al., 2014). We developed the simulatorZ package to create 
collections of independent genomic datasets with realistic properties and outcome 
variables generated from a known risk model. simulatorZ also implements the Más-o-
menos algorithm (Zhao et al., 2014, Donoho and Jin, 2008) and provides basic facilities 
for cross-validation and cross-study validation of prognostic models. 
Simulation of independent datasets. The simulation procedure contains three steps. The 
first is a non-parametric bootstrap at the dataset level, in which studies are sampled with 
replacement from the list of original studies. This estimates the variability due to 
sampling of studies from a “super-population” of studies (Hartley and Sielken, 1975). 
The second step is another non-parametric bootstrap at the patient level, where 
observations are sampled with replacement from each dataset selected in step 1. In the 
final step, a linear model is fit to the original datasets, then used to simulate new outcome 
on the simulated datasets (parametric bootstrap). 
 For studies with time-to-event outcome, we fit a proportional hazard (PH) model 
to the data: 
𝑀𝑡𝑟𝑢𝑒
𝑗
: 𝜆𝑗(𝑡|𝑥) = 𝜆0
𝑗




 is the PH model for the 𝑗-th dataset, whose hazard function is 𝜆𝑗(𝑡|𝑥), with 𝑥 as 
covariates. 𝜆0
𝑗
(𝑡) is the baseline hazard function for this study. 𝛽 represents the regression 
coefficients. 
 This generative model in step 3 combines the truncated inversion method (Bender 
et al., 2005), the Nelson-Aalen estimator (Nelson, 1969, Nelson, 1972, Aalen, 1978) for 




scores (Binder and Schumacher, 2008). We first use CoxBoost to obtain coefficients of 
linear predictors fitted to the original datasets, using the genes plus the clinical covariates, 
such as tumor size, debulking, histological grade and patient age, as predictors. The 
prognostic covariates were included to be mandatory unpenalized. We also obtained the 
Nelson-Aalen estimator of baseline cumulative survival and censoring hazard, which, 
together with the CoxBoost coefficients and the above equation, define the “true” models 
of survival for each dataset. Finally, we have: 
𝑈 = 𝑆(𝑇) = exp (−𝐻0(𝑇) ∗ exp(𝛽
𝑇𝑥)) ∼ 𝑈𝑛𝑖(0, 1) 
𝐻0 is the baseline cumulative hazard for the lifetime random variable 𝑇. 𝑆 denotes the 
survival function. We sample two independent, uniformly distributed variables 𝑢1 and 

















 are the inverses of baseline cumulative survival and censoring hazard, 
respectively. These are inverted by finding the point on the timeline such that the values 
calculated by −log (u) ∗ exp (−βT𝑥) are closest in absolute value to the cumulative 
hazards. The simulated survival response is the smaller one between 𝑇 and 𝐶. 








𝑃𝑗 denotes the probability of a sample in study 𝑗 to have the disease. Here, for studies 




model coefficients 𝛽. After fitting the model and estimating the probability 𝑃𝑖
𝑗
 for a 
sample 𝑖 in study 𝑗, we draw a value from the Bernoulli distribution 𝐵(𝑃𝑖
𝑗
) as the 
simulated outcome for that sample. 
Summary of within and across-study model performances. We selected the Más-o-
menos algorithm (Zhao et al., 2014, Donoho and Jin, 2008) and ridge regression (Hoerl 
and Kennard, 1970) as examples of predictive models to generate risk scores on the 
simulated datasets. It has been shown that these algorithms perform comparably to more 
complicated methods in the microarray datasets that we use (Bernau et al., 2014, Zhao et 
al., 2014). We repeated 100 simulations and model validations for each dataset/algorithm 
combinations. These include breast cancer microarray data with Más-o-menos and ridge 
regression methods, ovarian cancer microarray collection with the Más-o-menos 
algorithm, ovarian cancer microarray and RNA-Seq compendium with the Más-o-menos 
algorithm, and metagenomic studies with Más-o-menos, and ridge regression. We 
estimated the model accuracy with C-indices for studies with time-to-event outcome, and 
area under ROC curve (AUC) for studies with binary outcome. 
 In each of 100 iterations, we simulated a list of independent datasets of sample 
size 𝑛 = 150 using the “original studies” and the three-step bootstrap approach. We then 
generated a matrix of accuracy estimates for all combinations of training and test sets 
(Bernau et al., 2014). Cross-study validation (CSV) performance was summarized by the 
simple average of accuracy estimates for training and validation across all pairs of 
independent studies (off-diagonal elements of the matrix), and performance of the 4-fold 




process was repeated while altering potential sources of across-study heterogeneity, as 
described in the sections below. The above methods are summarized in Figure 3.1. 
 
Figure 3.1. A schema of this study. Simulation methods (using the breast cancer microarray 
studies as an example) are summarized in this flow chart. 
Datasets Breast cancer microarray datasets, ER+ individuals and DMFS response
Cleaning
• Linear scaling of expression values
• Missing values in gene expressions filled with KNN imputation
• Remove 60% low variance genes
• Remove duplicate samples or samples with missing values
• Remove studies with too few samples
• Curation of covariates: size, age, grade  (Supplementary table 1 for availability)
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Comparison of model accuracy using the RNA-Seq study. The methods for the RNA-
Seq study differed due to the availability of only a single RNA-Seq study with 
comparable outcome to the microarray studies. We compared cross-validation within this 
study to training and validation across different data types (one microarray and one RNA-
Seq study). During the simulations, we skipped the first bootstrap step which re-samples 
studies from the collection, in order to keep track of the RNA-Seq study among the other 
microarray datasets. We generated the matrix of accuracy estimates as before. When 
comparing model performances between within and across study validation, we limited 
the comparison to only when the RNA-Seq study is involved. This means that, in each 
simulation, we select the row and the column of the performance matrix which 
correspond to the RNA-Seq study. The performance of cross-validation is the diagonal 
element located at the intersection of the row and the column. The cross-study 
performance is summarized by averaging over all remaining elements within the row and 
the column. 
Clinical covariates 
 To simulate studies with similar distributions of a single clinical covariate, such 
as dichotomized tumor size, debulking, or of young and old patients, we first define the 
overall proportions of patients for that covariate using the proportions in the union of all 
original studies. We then changed the probabilities for bootstrap resampling on the 
individuals, so that on average, each simulated study would have proportions of patients 
equal to the overall proportions of the covariate. To balance on multiple covariates, we 




identical joint probability distributions of the clinical/pathologic covariates across 
datasets. For example, we denote the proportion of individuals with age larger than 70 
years and suboptimal debulking status in all ovarian cancer studies combined as 𝑃𝑐𝑜𝑚𝑚𝑜𝑛. 
Such proportion in a study 𝑠 alone is denoted as 𝑃𝑠. Then in the simulated study 
resampled from study 𝑠, patients with age larger than 70 years and suboptimal debulking 
status will be resampled with a probability that is proportional to 𝑃𝑐𝑜𝑚𝑚𝑜𝑛/𝑃𝑠, which is 
scaled to one for all individuals in study 𝑠. Re-weighting of the sampling probabilities, 
rather than enforcing strict equality of proportions, reflects the reality that these 
proportions are subject to sampling variation. 
Mixed-effect models. We quantify the impact of changing the proportion of covariates 
on the cross-study prediction accuracy by a regression approach, implemented via mixed-
effect models. These are implemented in the two compendia of microarray studies. We 
established a “baseline” scenario of 100 simulations based on the original studies, 
without any manipulation of sources of heterogeneity. We then performed another 100 
simulations where we changed the bootstrap re-sampling probabilities at the patient level 
to produce, on average, equal distributions of covariates in each study. This scenario is 
called “balancing covariates”. These simulations produce 100 matrices of C-index for 
each of the two scenarios, “baseline” and “balancing covariates”. 
 The validation matrices from the two scenarios are then paired together: the first 
matrix from “baseline” is paired with the first one from “balancing covariates”, then the 
second is paired with the second, ..., the 100th is paired with the 100th. These pairs of 




are used to compute the changes in cross-study validation accuracy, and the changes in 
the proportions of subjects in each covariate subgroup. For each off-diagonal position in 
the matrix, we calculate the change in C-index as the value in “balancing covariates” at 
that position minus the corresponding value in “baseline”. Also, for the same position, 
there is a pair of training/test sets for “baseline”, and another for “balancing covariates”. 
We compute the difference between the proportions of patients in the training (test) set 
for “balancing covariates” and the proportions in the training (test) set for “baseline”. 
This difference will serve as a potential predictor for changes in the C-index. 
 We then fit the model: 
𝒚𝑖|𝑩 = (𝑏𝑖0, 𝒃𝑖
𝑇) ∼ 𝑁(𝑏𝑖0 + 𝑋(𝜶 + 𝒃𝑖),  𝜎
2),           𝑩 ∼ 𝑁(0, Σ) 
For 𝑛 independent studies in a single simulation 𝑖, 𝒚𝑖 represents the changes in C-index. 
Each 𝒚𝑖 , 𝑖 = 1,2, … ,100, is a vector of length 𝑛 ∗ (𝑛 − 1) corresponding to all possible 
training/test set pairs in the 𝑖-th simulation. The design matrix 𝑋 contains predictors 
which include the changes in the covariate distributions in the training and the test set, as 
well as a third interaction term. Entries in 𝑋 are grouped by simulation indices (𝑖). 𝑋 has 
𝑛 ∗ (𝑛 − 1) ∗ 100 rows, accounting for all cross-study training/test set pairs across the 
100 simulations. 𝜶 = (𝛼1, 𝛼2, 𝛼3)
𝑇 is a vector of fixed effects. The three dimensions 
correspond to the changes of covariate proportions in the training and test set, and the 
interaction term. In the 𝑖-th simulation, 𝑩 equals to (𝑏𝑖0, 𝒃𝑖
𝑇), 𝒃𝑖 = (𝑏𝑖1, 𝑏𝑖2, 𝑏𝑖3)
𝑇 . They 
serve as a vector of normally distributed random effects, with mean and variance 




 Having the coefficients vary across simulations accounts for the potential inherent 
correlations in the observations within each simulation group, which uses the same list of 
simulated datasets. The observations are independent across groups, given that the 
simulated datasets are independent. It is modeled as having no intercept in the fixed 
component because the average difference over many simulations must be zero when 
there is no difference in the covariate distribution or the generating model for these two 
validation matrices. However, there will be random variation across simulations, for 
which we include an intercept in the random component. This model is fit on every 
covariate for the microarray dataset/algorithm combinations. 
Expression covariance 
 To investigate the potential impact of heterogeneity between gene expression 
levels in different datasets, we compared the baseline case to the case where we only use 
genes with high Integrative Correlation (Parmigiani et al., 2004, Garrett-Mayer et al., 
2008) between every dataset pair. Briefly, we first calculated the Pearson correlation 
matrix of each gene expression matrix. For each pair of datasets, the Pearson correlation 
of the 𝑘-th rows of the two correlation matrices is the Integrative Correlation of gene 𝑘. 
We did a grid search for the threshold of the Integrative Correlation, such that around 
1000 genes with the highest Integrative Correlation scores between every pair of original 
datasets were included. We also used arbitrary cut-offs 0.4 for breast cancer microarray 
studies and 0.2 for ovarian cancer microarray datasets, as a comparison with selecting 






 We equalized the “true models” of each dataset. In each simulation, we randomly 
select an original study in the third bootstrap step, and use its corresponding “true model” 
to simulate the new outcome for all re-sampled studies from the first two bootstrap steps. 
For studies with time-to-event outcome, we equalized separately the coefficients of the 
linear risk score, and the baseline hazard function. For studies with binary outcome, we 
used identical model coefficients. 
Results 
 We first detail our observations from the cancer microarray studies of patient 
survival because they provide the greatest sample size, then summarize RNA and whole 
metagenome sequencing results which are broadly consistent with these results. In 
original and simulated data, we observed a substantial loss of prediction accuracy in 
cross-study validation (CSV) when compared to cross-validation (CV). Reductions were 
approximately 0.04 on the C-index scale, and 0.12 on the AUC scale. We manipulated 
aspects of the simulated data to establish that reducing heterogeneity in the sources we 
investigate is not sufficient to eliminate the gap between across- and within-study 
prediction accuracy. Using identical “true models” is most effective in reducing this 
difference. Figures 3.2 and 3.3 summarize our results across multiple omics platforms, 






Figure 3.2. Simulation results comparing performances of cross-validation and cross-study 
validation. The “Baseline” scenario does not modify any source of heterogeneity. In “Rebalanced 
covariates”, we change the re-sampling probability to match the distribution of covariates. 
“Filtered genes” considers only genes with high Integrative Correlation. “Same hazard” uses the 
same cumulative hazard but different coefficients for simulations using microarray studies with 
time-to-event outcome. “Same models” uses the same data generating models. The numbers 
within the boxes show the median of the distributions. We observe that the sources of 
heterogeneity investigated in this work do not fully account for the loss of accuracy comparing 




































































































































































































































Figure 3.3. Simulation results comparing CSV to CV for evaluating Más-o-menos risk 
prediction models in ovarian cancer microarray and RNA-Seq studies. Colored boxes 
represent C-indices collected in within and across-study validation when RNA-Seq data is 
involved. White/grey boxes represent results using only microarray studies. Note that the 
microarray simulations in this figure are different from those in Figure 3.2. In this figure, the 
comparison is limited to the TCGA study, which contains only the 190 overlapping samples 
between the microarray and RNA-Seq platforms. 
Simulation of microarray studies 
 The following results are discussed in the context of the microarray studies. We 
recapitulated the major properties of these two collections of studies in a three-step 
bootstrap simulation procedure. The simulation studies maintained a realistic difference 
in validation accuracy as estimated within and across studies by the C-index. This 
difference is seen for both ridge regression and the Más-o-menos method, in breast 
cancer and ovarian cancer (see panels “Baseline" in Figure 3.2). 
Eliminating heterogeneity in clinical factors 
 To establish whether eliminating heterogeneity in known clinical factors could 































































probabilities to balance tumor size, grade and patient age for the breast cancer data, and 
age and debulking status for the ovarian cancer data (Figure 3.4). Proportions of these 
factors were then the same, in expectation, for each simulated dataset. For both cancer 
types, the differences between CV and CSV are not eliminated (Figure 3.2, “Rebalanced 
covariates”). In this scenario, differing distributions of these covariates does not 






Figure 3.4. Comparison before and after balancing covariates in the microarray studies. It 
is to illustrate the balancing effect after we adjust the probability of re-sampling. The single bar 
on the most right shows the overall distribution of the covariate across all original datasets, which 
we expect to be the distribution of this covariate in each simulated set after balancing. From left 
to right, every two adjacent bars represent the distribution in one data set before (the left bar) and 
after (the right bar) balancing. Changing the probability will not make the proportion of levels 
after balancing equal to the overall distribution, so the bars are not exactly the same. But we can 
observe that the distributions after balancing are closer to the overall distribution than those 
without balancing. Severe bias is adjusted such as tumor size in VDX and age in TRANSBIG. 
The figures prove that we actually balanced the prevalence of covariates as we wanted. It 
enhances our conclusion about the irrelevance of covariate distributions to C-index performances. 
 In addition, we built a linear model for every covariate, each model associating 




summarizes the results of this analysis and highlights which covariates have an effect on 
CSV in the two methodologies used. Interestingly, even covariates that are prognostic of 
the survival outcome do not necessarily significantly relate to the prediction accuracy 
changes. 
Breast Cancer 
 Más-o-menos Ridge regression 
Age Train 0.0216 (0.0095) * -0.0015 (0.0090) 
Test 0.0187 (0.0105) . 0.0147 (0.0118) 
Interaction -0.0609 (0.0474) 0.0675 (0.0396) . 
Size Train -0.0204 (0.0135) 0.0032 (0.0184) 
Test -0.0091 (0.0142) 0.0205 (0.0240) 
Interaction -0.0020 (0.0773) -0.0028 (0.1374) 
Grade Train (high) -0.0457 (0.0175) ** -0.0105 (0.0193) 
Test (high) -0.1045 (0.0212) *** 0.0176 (0.0263) 
Interaction (high) -0.1417 (0.0699) * 0.0400 (0.0568) 
Train (mid) -0.0338 (0.0198) . -0.0110 (0.0261) 
Test (mid) -0.1037 (0.0274) *** 0.0166 (0.0339) 
Interaction (mid) 0.2117 (0.1081) . -0.0116 (0.1010) 
Ovarian Cancer 
 Más-o-menos  
Age Train -0.0136 (0.0222)  
Test -0.0339 (0.0261)  
Interaction 0.4283 (0.4845)  
Debulking Train 0.0201 (0.0146)  
Test -0.0093 (0.0141)  
Interaction -0.1180 (0.1392)  
Standard errors of coefficients in parentheses 
Significant codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
Table 3.6. Results of the mixed-effect models. This table summarizes the fixed effects (with 
standard errors in parentheses, and stars to denote significance) for the mixed-effect model. Train, 
test and interaction refer to the changes in the proportion of the covariates after balancing from 
the baseline scenario, which correspond to (𝜶𝟏, 𝜶𝟐, 𝜶𝟑). The changes in proportions of high- and 





Filtering genes by Integrative Correlation 
 We filtered genes to include roughly the top 1000 genes with the highest 
Integrative Correlation (Parmigiani et al., 2004, Garrett-Mayer et al., 2008) between 
every pair of original datasets. We implemented this by searching on a grid for the 
required threshold of IC. The threshold is 0.24 for breast cancer (999 genes), and 0.15 for 
ovarian cancer (1002 genes). After filtering these genes on the original datasets, the 
differences between CV and CSV are only slightly reduced for breast cancer, and not 
reduced for ovarian cancer (Figure 3.2, “Filtered genes”). 
 As an alternative to fixing the size of the gene set, we used thresholds of 0.4 for 
breast cancer and 0.2 for ovarian cancer. Both CV and CSV perform slightly worse using 
the fixed thresholds compared to the grid search, as the stricter filtering results in loss of 
good predictors. The observed pattern remains that the gap in accuracy is not eliminated 
(Figure 3.5), which suggests that the result is robust to the choice of thresholds. Filtering 
genes to enforce similar covariance structures across studies, as would be expected in the 






Figure 3.5. Boxplots comparing the impact of different thresholds of Integrative Correlation 
on the simulation results, using the breast cancer / Más-o-menos combination as an 
example. Baseline: simulations where no sources of heterogeneity is altered, which corresponds 
to panels “Baseline” in Figure 3.2. Grid search: we searched on grid for the threshold such that 
the top 1000 genes with high Integrative Correlations are selected. Arbitrary threshold: the cut-off 
values of 0.4 for breast cancer and 0.2 for ovarian cancer are used, which includes 343 out of 
5307 genes for breast cancer datasets, and 590 out of 7484 genes for ovarian cancer datasets. The 
difference between CV and CSV is not reduced with either approach, which is consistent across 
all data / algorithm pairs. 
Using the same true model 
 True models of the experimental sets with time-to-event outcome differ in both 
baseline survival and risk coefficients. Figure 3.6 shows the average probability of 
survival in each dataset and for all datasets combined, which explains what we mean by 
the differences in the true models. Differences in baseline survival mean that survival 
across all patients is better in some datasets than others, for example varying between 
60% and nearly 90% 5-year survival. We equalized both coefficients and baseline 
hazards across studies, while allowing the joint distribution of covariates and the gene 



























Figure 3.6. Average probability of survival of each set and the combination of all sets for 
breast cancer. We compute an expected survival function for each individual in every dataset 
using the true cumulative hazard and the linear predictor. We then average these survival 
functions across patients within each dataset. Colored lines represent average survival functions 
in each original set. The black line shows the average survival function of all datasets combined. 
This figure shows the differences in the “true model” from each original study. 
 Utilizing true survival models that are identical in both baseline hazard and 
coefficients moderately reduces the difference between within and across-study 
validation when training Más-o-menos for both breast and ovarian cancer studies. It 
greatly reduces the within to across-study performance gap when ridge regression is used 
for both cancer types (Figure 3.2, “Same models”). In addition, equalizing only the 
baseline survival functions but not the model coefficients barely reduces the performance 



































Generalization across data types 
 We now illustrate the results from simulations involving sequencing-based 
studies. First, we summarized the results of training and validating the prediction models 
using the TCGA RNA-Seq study. Figure 3.3 shows the comparison of results evaluating 
prediction models across microarray and RNA-Seq data types, with those using only the 
microarray studies. We observed high similarity in the distribution of accuracy estimates 
between using only microarray studies, and a combination of RNA-Seq and microarray 
studies. Including only highly comparable genes in the original studies brings down the 
cross-validation performance. Among the sources of heterogeneity we investigate, 
enforcing identical “true models” is most effective in reducing the performance gap, 
while maintaining the cross-validation performance at a comparable level to the 
“baseline" simulations.  
 These observations are further validated in the metagenomic studies with binary 
outcome of type-II diabetes vs. control (Figure 3.2). We observed high variance in AUC 
scores of models in across-study validation compared to cross-validation. Reducing 
heterogeneity in clinical factors and in gene measurements barely influences the 
difference between within to across-study validation. Using identical “true models” 
greatly reduces the performance gap.  
 These results demonstrate generalizability of key results across various data types 
(gene expression microarray, RNA-Seq, and whole-metagenome shotgun sequencing), 




known sources of heterogeneity (age, tumor grade and size, suboptimal ovarian 
carcinoma debulking, and BMI), as well as for both time-to-event and binary outcomes. 
Discussion 
 It is commonly assumed that heterogeneity in experimental platforms or 
procedures, and differences in patient cohorts, compromise the comparability of 
independent datasets and the application of omics-based prediction models across studies. 
This could be addressed by minimizing potential sources of heterogeneity, for example 
by enforcing precise criteria for patient inclusion. However, such narrowing has costs in 
sample size and potential generalizability of findings. To the best of our knowledge, no 
study has carried out a systematic approach to assessing the impact of suspected sources 
of heterogeneity on the across-study performance of prediction models. We used several 
compendia of datasets, generated from microarray, RNA sequencing, and whole-
metagenome shotgun microbiome sequencing, with study heterogeneity from known and 
unknown sources, to perform this exploration. We emphasize that the presence of 
heterogeneity between studies, both measured and unmeasured, is necessary to our 
investigation. 
 When training and validating prediction models in these collections of studies, we 
observed a discrepancy in performance for models validated in fully independent studies 
when compared to standard cross-validation. For risk prediction of overall survival in 
compendia of breast and ovarian cancer datasets, independent validation statistics were 
0.04 worse on the C-index scale when compared to cross-validation. For predictions of 




worse on the AUC scale in across-study validation compared to within-study validation. 
These differences in model performance are widespread and sufficiently sizable to 
question the utility of cross-validation for deciding whether to pursue further 
development of a prediction model developed and validated on a single dataset. We thus 
investigated the contributions of known and unknown sources of heterogeneity to this 
discrepancy. 
 In simulations mimicking these compendia of studies, spanning various data 
generation technologies and types of outcome, reducing heterogeneity in important 
clinical covariates did not reduce the discrepancy between CV and CSV. This finding 
highlights that it should not be assumed that known differences in the composition of 
different cohorts will negatively impact the application of prediction models across them, 
or that stricter inclusion criteria will improve the models' cross-study validation. Several 
factors are in play. Covariates define strata that are generally associated with different 
degrees of predictability - in some strata the predictors may be more effective than in 
others in predicting the outcome. Thus, rebalancing covariates may result in better or 
worse prediction accuracy depending on which strata are given greater weight. Also, 
covariate mix in the training sample affects properties of the training algorithm, 
particularly when relevant covariates are not or cannot be modeled explicitly. Thus, it is 
difficult to draw general conclusions from individual case studies, but it should not be 
assumed that stricter inclusion criteria will improve prediction models.  
 Nonetheless, it is interesting to associate the changes in proportions of clinical 




association with mixed-effect models in the collections of cancer microarray studies 
where some covariates strongly affect survival, but found that their marginal distributions 
do not have much impact on the cross-study stability of predictions of survival. 
Heterogeneity in the prevalence of covariates like debulking and patient age for ovarian 
cancer can impact overall survival in different cohorts, but not the ability to predict 
overall survival. 
 Similarly, in these compendia of datasets spanning at least 11 different labs and 
various microarray and sequencing platforms, enforcing good expression measurement 
comparability through selection of genes with high Integrative Correlation only 
moderately closed the gap between cross-study validation and cross-validation in certain 
data algorithm combinations. Ensuring fully identical models of the association between 
gene expression and outcome for each study is most powerful in reducing this 
discrepancy. Thus in these datasets, the most important sources of heterogeneity from the 
perspective of cross-study validation are likely to be those affecting the relationship 
between predictors and outcome, and are not likely to be included in the published 
datasets. For example, these could arise from different relationships between covariates 
and unmeasured confounders, or from different marginal distributions of these 
confounders. 
 We used a hybrid parametric/non-parametric bootstrap simulation approach to 
generate potentially different outcomes for simulated samples that are resampled from the 
same individual. The parametric step made it possible to simulate the removal of 




respect to coefficients and baseline hazards. Theoretically, we could perform rebalancing 
of covariates in a fully non-parametric approach. However, this would require an 
extension of the .632 or related approaches (Efron and Tibshirani, 1997) to correct for 
over-optimism in estimated model performance caused by resampling of both individuals 
within studies and entire studies within the collection. To the best of our knowledge, such 
a method is not yet described for a cross-study bootstrap. This would be an interesting 
area for future research.  
 This study has several limitations. We focus on AUC and C-Index to evaluate the 
discrimination accuracy of the prediction models, even though these statistics are not 
directly relevant to clinical implementation. However, they provide advantages of 
simplicity while adequately capturing the phenomenon of degraded cross-study 
validation performance relative to cross-validation. The additional model selection in 
determining thresholds, and necessary assumptions about prevalence to calculate positive 
and negative predictive values, are complicating factors that may distract from rather than 
provide additional insight from the basic phenomenon of degradation in cross-study 
validation performance. Furthermore, sampling designs of the studies analyzed are not 
amenable to validation of positive/negative predictive value without further simulation. 
In independent validations of predictive value, we would expect prevalence to be an 
additional source of potential heterogeneity between study populations, but for the 
conclusions of this manuscript to remain relevant.  
 We focus mainly on altering one source of heterogeneity at a time, and were only 




age, tumor size and grade for breast cancer; age and debulking status for ovarian cancer; 
BMI for type-II diabetes. But our proposed approach shows how the impact of known 
sources of study heterogeneity can be assessed for their impact on prediction modeling, 
and that the most obvious heterogeneity may not be the most important. 
 Despite the limitations, our work has several novel and important contributions. 
We introduce a novel approach to quantify the impacts of heterogeneity in observed 
confounders, predictor covariance, and unmeasured confounding on cross-study 
prediction accuracy. In addition, our results of rebalancing covariates have an important 
implication - that it is questionable whether studying more clinically homogeneous 
groups justifies the loss of sample size in practice. This is a common but relatively 
unexamined practice that we challenge. We developed simulatorZ which automates all 
steps of these simulations including covariate balancing. One powerful feature of 
simulatorZ is that it can simulate data from one or more “omics” studies in a highly 
realistic way compared to typical synthetic data. Realistic, data-driven, simulated data is 
essential in evaluating newly developed computational methods. Recent studies have 
mentioned the utility of simulatorZ in evaluating methods for proteomics data (Gatto et 
al., 2015) and in validating replicable cross-study predictors for personalized medicine 
(Patil and Parmigiani, 2018). By publishing simulatorZ, as well as a code repository to 
reproduce the results of this chapter, we hope to encourage further investigation of the 





 To implement the simulation approach, we developed the simulatorZ package and 
made this available through Bioconductor. Scripts for reproducing the results are stored 
and documented at https://bitbucket.org/zhangyuqing/datasetheterogeneity. 
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Chapter 4. Addressing unwanted batch effects in prediction via ensemble learning 
Adapted from the following manuscript: 
Zhang, Y., Johnson, W. E., and Parmigiani, G. (2019). Robustifying genomic classifiers 
to batch effects via ensemble learning. bioRxiv, 703587. 
Introduction 
 Ensemble learning is a well-established method, but it has only recently been 
discussed in the context of training replicable genomic predictors. It was found that 
ensembles of learners trained on multiple studies generate predictions with more 
replicable accuracy (Patil and Parmigiani, 2018). In their framework, a cross-study 
learner (CSL) is specified by three choices: a) a data sub-setting strategy; b) a list of one 
or more single-study learners (SSLs), which can be any machine learning algorithm 
producing a prediction model using a single study; and c) a combination approach 
utilizing multiple prediction models to deliver a single prediction rule. Later research 
provides theoretical insights in the comparison between merging and ensembling in 
training learners from multiple studies, and conclude that although merging studies is 
better than ensembling when the studies are relatively homogeneous, ensembling yields 
better performing models when the level of study heterogeneity is higher (Guan et al., 
2019). 
 In this chapter, we continue the discussion with regard to training predictors with 
generalizable performance across-studies, and aim to address the unwanted impact of 
batch effects on binary classification problems. Strictly, batch effects refer to technical 




are often used in a broader sense, with varied definitions for different contexts (Lazar et 
al., 2012). It is common to use batch adjustment methods for integrating not only 
technical batches, but also datasets across experimental platforms or types of biological 
samples, for the same purpose of analysis (Larsen et al., 2014, Butler et al., 2018, Bobak 
et al., 2019).  
 It was previously mentioned that existence of batch effects threatens the 
reproducibility of genomic findings (Kupfer et al., 2012), and many batch effect 
adjustment methods have been proposed for gene expression microarray (Leek and 
Storey, 2007, Johnson et al., 2007, Gagnon-Bartsch and Speed, 2012, Gagnon-Bartsch et 
al., 2013, Benito et al., 2004) and sequencing data (Leek, 2014, Risso et al., 2014). These 
methods share the general idea to first merge all batches, estimate parameters 
representing differences in batch distributions, and then remove them from the data, 
resulting in a single adjusted dataset for downstream analysis. Here we adopt a different 
perspective, and propose to address batch effects with cross-study learning as mentioned 
above (Patil and Parmigiani, 2018). In our case, we subset the data by batch, and use the 
same CSL with batches in place of studies. Contrary to the traditional batch effect 
adjustment methods, our proposed framework is based on the integration of predictions 
rather than that of data. This is a simpler task for prediction, as it operates in one 
dimension rather than many. Also, it is possible to reward predictors that show good 
performance across batches and thus altogether ignore, rather than trying to repair, 




 In this chapter, we explore using ensemble learning in the context of batch effect 
adjustment for the first time. We provide both realistic simulations and real data 
examples to demonstrate the utility of our ensembling framework, and compare it with 
traditional merging strategies for addressing batch effects. 
Materials and methods 
Addressing batch effects via ensemble learning 
 We structure the problem as follows: in a binary classification problem on 
genomic data, we have a training set for learning prediction models (𝑆𝑡𝑟𝑛), and another 
independent test set (𝑆𝑡𝑠𝑡) where predictions are to be made. Subjects in the training set 
are associated with a binary label indicating their phenotype. Examples of the phenotype 
could be disease status (e.g. cancer versus normal) or response to a treatment. In addition, 
expressions of genes for all individuals are profiled for use as predictors. Individuals in 
the test set also have measured gene expressions, and the goal is to train a model that can 
accurately predict the disease label for them based on their gene expression profiles. We 
assume that the training set is generated in 𝐵 batches 𝑆𝑡𝑟𝑛
1 , 𝑆𝑡𝑟𝑛
2 , … , 𝑆𝑡𝑟𝑛
𝐵 , possibly due to 
practical or technical restrictions. Each batch contains a sufficient number of samples to 
train a prediction model. We assume both additive and multiplicative batch effects 
(Johnson et al., 2007), which cause differences in the mean and the variance of gene 
expressions across batches. 
 Consider a collection of 𝐿 learning algorithms to use for training. Cross-study 
learning begins by training each of the algorithms within each of the batches. This results 
in the collection ?̂?𝑏
𝑙(𝑥), 𝑙 = 1,2, … , 𝐿 and 𝑏 = 1,2, … , 𝐵, where ?̂?𝑏




function trained on batch 𝑏 with learning algorithm 𝑙. In the binary classification setting, 
?̂? are the probabilities of samples belonging to the positive class. The final cross-study 
learner’s (CSL) prediction is calculated by a weighted average of predictions from each 
model, that is: 







 The performance of a CSL relies critically on the weights 𝑤𝑙𝑏 , as these have the 
function of rewarding elements of the ensemble which show stable predictive 
performance across batches. We explore five weighting strategies, which fall into three 
categories (Patil and Parmigiani, 2018). The first is sample size weights, which uses 
scaled batch sizes as weights for models trained in the corresponding batches, and makes 
not effort to reward robustness to batches via weights. The second is cross-study weights, 
for which we evaluate how well each learned model performs when applied to the other 
batches within the training set, and assign higher weights to models that have better 
prediction performances. The last category is stacking regression weights (Breiman, 
1996), for which we use each model to make predictions of the training data, and 
estimate the weights as regression coefficients between stacked predictions of the training 
samples and their labels. The association coefficients are estimated using non-negative 






 We use a collection of 7 RNA-Seq and microarray studies targeting subjects 
infected with tuberculosis (TB) to apply and evaluate our ensemble learning method, and 
make comparisons with the traditional strategy of merging followed by batch adjustment 
(for short “merging”). Subjects involved in this collection of studies can be divided in 
three phenotypes based on their disease progression status: 1) latent infection (LTBI) / 
nonprogressing, 2) in “progression”, or those that will progress to disease in the near 
future, and 3) active TB disease. For simplicity and sample size considerations, we use 
two types of patients in each analysis to form a binary classification problem, and focus 
on different phenotypes for simulation and application of our methods. In simulations, we 
focus on predicting progressors against non-progressors, as this separation yields the 
largest sample size in the training set. In real data, since there are no known batch effects 
within any single study, we aim to separate subjects with latent infection from those with 
active disease instead, so we have sufficient number of studies in the collection. We 
merge studies for training while treating the differences between studies as “batch 
effects”. 
 Table 4.1 summarizes information on the samples used in simulation studies and 
real data analysis. This collection of studies shares a similar purpose: to develop genomic 
biomarkers for patients with different tuberculosis progression status. It is common in 
practice to consider them as “batches” for the uniform purpose. However, studies differ 
in both biological and technical aspects. For example, study A (Zak et al., 2016) targets 




measures only children under the age of 15. The remaining studies contain subjects in a 
much wider age spectrum, including both children and adults. In the collection, the 
geographical source of populations includes India (study D), the United States (study E), 
and different regions in Africa (studies A, B, C, F, G). Studies are also generated from 
various array and sequencing platforms (Table 4.1). While jointly using the studies as 






Table 4.1. Summary statistics of the TB datasets used in simulation studies and real data 
applications. #Subjects: total number of individuals in each study. #Pos: number of positive 
samples. They refer to progressors in simulation studies, and active patients in real data 
application. The negative samples are subjects with latent infections in both cases. Prevalence: 
percentage of positive samples in the study. Note that study A targets only adolescents between 
ages of 12 and 18. Study C measures only children under the age of 15. The remaining studies 
contain subjects in a much wider age spectrum. Studies F and G are published together as two 
separate studies with different populations. The 7 datasets are generated using a variety of 
technologies. 
Simulation for comparing merging and ensembling 
 We consider two datasets in simulation, A and B, which are collected from the 
African population, as described in Table 4.1. We use study A for training, and study B 
for independent validation. For the training set only, we randomly assign individuals to 
disjoint subsets which will be simulated to be batches, and simulate differences in the 
moments of gene expression distributions across batches as described below. No batch 
effects are added to the validation set. We train predictors using both merging and 




A RNA-Seq Illumina HiSeq 2000 181 77 (42.5%) Zak et al., 2016 
B RNA-Seq Illumina HiSeq 2000 399 95 (23.8%) Suliman et al. 2018 
Applications 
A RNA-Seq Illumina HiSeq 2000 120 16 (13.3%) Zak et al., 2016 
C microarray Illumina HumanHT-
12 V4.0 expression 
beadchip 
70 20 (28.6%) Anderson et al., 2014 
D RNA-Seq Illumina NextSeq 
500 
44 25 (56.8%) Leong et al., 2018 
E microarray Affymetrix Human 
Gene 1.1 ST Array 
70 35 (50%) Walter et al., 2016 
F microarray Illumina HumanHT-
12 V4.0 expression 
beadchip 
94 46 (48.9%) Kaforou et al., 2013 
(South Africa) 
G microarray Illumina HumanHT-
12 V4.0 expression 
beadchip 





ensembling on this dataset with simulated batch effects, then make predictions in the 
other independent study. We evaluate the two approaches using discrimination in the 
independent study. Details follow. 
Simulation of batch effects. We transformed the sequencing data into the logarithm of 
fragments per kilobase of transcript per million mapped reads (logFPKMs), and selected 
the top 1000 genes with the highest variances for building the classifiers. Then, we 
randomly took subsets of individuals from the training set to form 3 batches, each batch 
containing 10 non-progressors and 10 progressors. We then simulated batch effects 
across the 3 batches. 
 Our data generating model for batch effects is the linear model assumed in the 
ComBat batch adjustment method (Johnson et al., 2007). Specifically, we estimate two 
components from the original training data: 1) the expression of gene 𝑔 among the 
negative samples, and 2) the biological effect (i.e. the expression changes due to 
biological perturbations or conditions of interest). We then specify batch effect 
parameters affecting the mean (𝛾𝑔𝑏) and the variance (𝛿𝑔𝑏) of expression in gene 𝑔 
caused by batch 𝑏. Same as in ComBat, 𝛾𝑔𝑏 and 𝛿𝑔𝑏 are randomly drawn from hyper-
distributions 
𝛾𝑔𝑏 ∼ 𝑁(𝜂𝑏, 𝜏𝑏
2), 𝛿𝑔𝑏 ∼ 𝐼𝑛𝑣𝐺𝑎𝑚𝑚𝑎(𝜆𝑏, 𝜃𝑏) 
 ComBat assumes an additive batch effect for the mean, and a multiplicative batch 
effect for the variance. To set the hyper-parameters, we first specify a value to represent 
the severity of batch effects, as reported in columns 𝑠𝑒𝑣𝑚𝑒𝑎𝑛 and 𝑠𝑒𝑣𝑣𝑎𝑟  in Table 4.2. We 




(𝑠𝑒𝑣𝑣𝑎𝑟 ∈ {1,2,3,4,5}) for batch effect on the variance. Given a severity level for batch 
effects, we fixed values for 𝜏𝑏s and 𝜃𝑏s, so that the variance of 𝛾𝑔𝑏  and 𝛿𝑔𝑏 over genes 
are 0.01. We varied the mean of these two parameters, so that the hyper mean 𝜂𝑏 is 








, 𝑠𝑒𝑣𝑣𝑎𝑟) for 
the three batches. The parameters are then added or multiplied to the expression mean 
and variance of the original study. The characteristics of simulated batches are also 
summarized in Table 4.2. Figure 4.1 shows and example training set where we simulated 
3 batches with both mean and variance differences. 
𝑠𝑒𝑣𝑚𝑒𝑎𝑛 Batch 1 mean Batch 2 mean Batch 3 mean 
0 3.7 3.7 3.7 
3 0.7 3.7 6.7 
5 -1.3 3.7 8.7 
𝑠𝑒𝑣𝑣𝑎𝑟  Batch 1 variance Batch 2 variance Batch 3 variance 
1 1.12 1.50 1.29 
2 0.56 1.55 2.81 
3 0.52 2.21 3.19 
4 0.39 2.49 4.81 
5 0.31 3.17 5.98 
Table 4.2. Levels of simulated batch effects in mean and variance of gene expression. We 
created mean shifts and fold changes (FC) in average variances of genes across the three 
simulated batches. ComBat assumes additive batch effect for the mean expression. For example, a 
batch effect on the mean of 3 means that we subtract 3 on average from expressions in batch 1, 
and add 3 on average to expression values in batch 3. Values in batch 2 are not altered. On the 
other hand, batch effect on the variance is multiplicative. So, a batch effect of 4 on the variance 
means that in batch 1, the average gene variance is reduced to 1/4 of the original variance in data, 
while in batch 3, the average variance is inflated 4 times. Variance of batch 2 is changed to an 
intermediate level. The first column records the parameters we used in simulations, and 
correspond to the titles in Figure 4.2. The remaining three columns show the moments of 





Figure 4.1. PCA of the original study A, and an example training set with simulated batch 
effect. We generated the training set by first taking 3 random subsets from the original data in the 
study A (Zak et al., 2016), and treat them as 3 different batches. We then simulate batch effects in 
both mean and variance of gene expression across the three batches (see also Table 4.2). In this 
example, we simulated a mean difference of 3, and a variance difference of 4 across batches. 
Comparing ensemble learning with merging after batch correction. We then use the 
dataset with simulated batch effects to train classifiers for predicting patient phenotypes. 
We perform the ensemble learning strategy as described above. For the merging strategy, 
we pooled the three batches together, and applied ComBat to remove batch effects. We 
then used the whole adjusted data to train a single model, and make one set of predictions 
on the independent test set. We trained learners LASSO (Tibshirani, 1996), Random 
Forest (RF, Breiman, 2001), and Support Vector Machines (SVM, Cortes and Vapnik, 
1995), after performing the two batch adjustment strategies. In ensemble learning, we 
evaluated aggregating predictions both from a single learning algorithm (𝐿 = 1), and 
across all algorithms (𝐿 = 3). The accuracy of performance was measured by the area 
under ROC curve (AUC). We repeated batch correction and predictions to generate 100 




Applying ensemble learning to address real data batch effects 
 To demonstrate a realistic application setting for our ensemble learning method, 
we took 6 TB studies as summarized in Table 4.1. We iteratively treat each of these 
studies as the independent test set. The remaining studies are used as batches forming the 
training set. 
 The original data contains more than 15000 genes, resulting in too unfavorable a 
situation so serve as a comparator for our methods. For example, LASSO was not able to 
get a prediction AUC above 0.5 on the independent samples. We thus prefiltered genes to 
select a subset of the 1000 most highly variable, and used the same subsets of genes for 
both ensembling and merging. 
 We trained 3 learning algorithms: LASSO, RF, and SVM, and integrated 
predictions both from each single learning algorithm, and from all three learning 
algorithms in the ensemble framework. The remaining methods for batch effect 
adjustment, predictions, and model evaluations are the same as those for simulation 
studies. We performed 100 bootstrap replicates on the test set, to obtain a confidence 
interval for model performance scores. 
Results 
Impact of mean and variance batch effects on discrimination of predictions 
 Figure 4.2 summarizes results over 100 simulated datasets, representative of the 
patterns we observe across simulation studies. The learner is Random Forests for both 
merging and ensembling. On the original training study without simulated batch effect, 




data, we observed drops in discrimination in the test set. Mean and variance batch effects 
affect prediction performance in different ways. Model discrimination is not strongly 
affected by batch if batch effect only affects the variance. A sufficient size of the mean 
differences across batches in the training set is necessary to cause a drop in prediction 
accuracy. On the other hand, when batch affects the mean, an increase in variance 
differences across batches will lead to a further drop in discrimination. 
 
Figure 4.2. Comparison between ensembling and merging when using Random Forests. 3 
out of our 5 choices of ensembling weights are displayed: batch size weights, cross-study 




Ensemble learning achieves more stable discrimination than merging at high severity of 
batch effects 
 Table 4.2 shows the levels of batch differences we created in simulation studies, 
corresponding to the results in Figure 4.2. We considered ensembling both using a single 
learning algorithm, and using all three learning algorithms together, and we observed 
similar results. At a low level of batch effects, with no mean difference and a variance 
fold change smaller than 3, the merging method yields better discrimination. However, 
we observed a turning point in the severity of batch effect, after which ensemble learning 
starts to achieve higher discrimination. This turning point is characterized by general 
stability or small improvements in the performance of the ensembling approaches and 
large drop-offs in the unadjusted and batch-adjusted merged data approaches. 
 The turning point in the magnitude of batch effects differs by the selected learning 
algorithms. When training with SVM, for example, we see that discrimination from 
ensemble learning is already comparable with that using the merging method at no mean 
batch effect and a variance fold change of 2 (Figure 4.3), though at this level, merging 
still out-performs ensembling when training with Random Forests. Also, at high level of 
batch discrepancies, stacking regression weights yield better prediction results than the 
sample-size weights when building ensemble with SVM alone, though they are more 





Figure 4.3. Comparison between ensembling and merging when using SVM. When training 
with SVM, we see that discrimination from ensemble learning is already comparable with that 
using the merging method at no mean batch effect and a variance fold change of 2, though at this 
level, merging still out-performs ensembling when training with Random Forests (Figure 4.2). 
 We also observed that ensembling across different learning algorithms does not 
necessarily improve the final prediction compared to ensembling with a single algorithm. 
We see in Figure 4.2 that ensemble learning across learning algorithms generates worse 




depends on the learners involved in the ensemble. When using Random Forests only, the 
sample size weights and the stacked regression weights generate better accuracy than the 
cross-study weights. But the latter is better in integrating across all algorithms. Note that 
despite the difference in rankings of the three types of weights, all three ensemble 
weighting methods out-perform merging and batch correction with ComBat at high level 
of batch differences. 
 Finally, we repeated the simulations with a larger sample size, and larger number 
of batches. To increase batch size, we took 3 subsets as batches, each containing 20 non-
progressors and 20 progressors, in contrast to our previous results which use 10 
individuals per condition per batch. For a larger number of batches, we took 5 subsets of 
subjects as simulated batches. We observed consistent patterns in both situations, as 






Figure 4.4. We observed consistent results between simulating batch sizes N=20 and N=40. 
In both cases, we have a completely balanced study design in each of the 3 batches. For N=20, we 
randomly sample 10 positive and 10 negative samples. For N=40, we sample 20 in each class. In 
both sample sizes, we observe that merging out-performs ensembling with smaller batch effects. 





Figure 4.5. We observed consistent results between simulating 3 and 5 batches. In both cases, 
we have a completely balanced study design in each of the batches. Same as in the other 
simulations, we found that merging out-performs ensembling at a lower level of batch effect. 
While as the severity of batch effect increases, ensemble starts to gain better prediction abilities. 
Application to predicting tuberculosis disease phenotype 
 We now present a classification case study using real data with batch effects. 
Specifically, we selected six studies to develop TB progression biomarkers, and 
iteratively treat one as test set, and use the others as batches for training. We applied both 
ensembling and merging to address batch effects, and trained 3 types of learning 
algorithms. Ensemble predictions are aggregated using each learning algorithm, and from 
all algorithms. To obtain a confidence interval of model performance, we generated 100 




severe and complicated than technical batch effects, this application example represents a 
high level of batch differences. 
 The cross-entropy loss and the weights assigned to learners trained from each 
training batch, using only random forest learners, are shown in Figure 4.6. Whenever 
study A is included as a batch in training, the stacking weights are dominated by weights 
assigned to the learner from study A. Meanwhile, cross-study weights consider it to be 
the worst-performing when generalizing to the other batches in the training set. In 
addition, though such patterns in the assigned weights are consistent across test sets, we 
observe different rankings of merging and the three ensembling methods in mean cross-
entropy loss when different studies are used as the test set. Cross-study weights achieve 
the lowest average loss among all methods on studies D, F and G, and among the three 
ensemble methods on study E, while stacking regression weights yield the worst loss. 
This ranking is reversed when A or C is used as the test set. These observations of model 
performance are consistent when aggregating predictions from all three learning methods, 





Figure 4.6. Mean cross-entropy loss and weights assigned to each single-batch learner, using 
6 TB studies and only RF learners. The rankings of methods change when different studies are 
used as the test set. In addition, when study A is included as a training batch, the stacking weights 
are dominated by weights assigned to the learner from study A, while cross-study weights 





Figure 4.7. Application of ensemble learning to predicting active TB against latent infection. 
We iteratively select one of the studies in Table 4.1 as the independent test study. The remaining 
studies are viewed as “batches” in the training set. The batches in this setting represent a strong 
level of batch effects. We trained LASSO, Random Forest, and SVM, then aggregated predictions 
from all three algorithms to construct the ensemble. The figure shows average prediction 
performance over 100 bootstrap samples of the test data, with error bars showing 95% bootstrap 
confidence intervals of performance measures. When the four homogeneous studies are used, the 
average performance using the three ensemble strategies are better than the merging strategy, 
which is consistent with observations from the simulation study at high severity of batch effects. 
 To investigate the reasons behind these observations, we have noticed and 
mentioned that the six studies target populations in different age spectrums. The two 
studies with different rankings of methods than the others, A and C, only include children 
or adolescents. It is well-established that young age is a risk factor for progression from 
TB infection to active disease (Narasimhan et al., 2013). Tuberculosis in childhood and 
adulthood is also different in clinical features and pathogenesis (Alcaïs et al., 2005). In 
our six datasets, we merged studies after z-score standardization within each study and 
selected 1000 genes with the highest marginal variance. Among these 1000 genes, we 
used limma (Smyth, 2005) to perform differential expression in each study and identified 




overlapping genes across studies, resulting in 11 up-regulated and 16 down-regulated 
genes that are common across studies. We measured the average expression of these up- 
and down-regulated genes in each study, as visualized their expression distribution in 
Figure 4.8. It is clear to see that the top differentially expressed genes are not those with 
the clearest biological signals in studies A and C. These results suggest that the difference 
in age being confounded with batch may explain the inconsistent observations in the six-
study analysis. For example, when training in the other batches and validating in A or C, 
the training data consists of a mixture of children and adults, in which we are not able to 





Figure 4.8. Expression distribution of up and down regulated differentially expression genes 
in each study. Studies A and C have different distribution patterns from the others, which is 





 We then took the four studies with subjects spanning a broader range of age, 
namely D, E, F, and G, and re-applied both ensembling and merging strategies. In this 
case, the four studies are more representative of what are usually considered “batch 
effects”, as they serve the same purpose for developing TB biomarkers for general 
populations. The bottom row in Figure 4.7 shows the mean cross-entropy loss of 
predictions, where ensemble predictions are aggregated across all 3 learning algorithms. 
We observed that the average ensemble learning performances are better than those of 
merging in all test studies.  
 Due to relatively small sample sizes, we also observed a high variance in model 
performance. Therefore, we also compared ensembling against merging within each 
bootstrap sample in the four-study analysis. The proportions of bootstrap samples where 
ensembling generates strictly lower mean cross-entropy loss than merging is summarized 
in Table 4.3, which shows that under almost all situations, addressing batch effects via 
ensemble learning yields more robustly performing models with respect to 
discrimination. These results are broadly consistent with our observations in simulations 
that when there are severe differences across batches, ensemble learning is a more robust 
strategy for addressing the impact of batch effects on prediction. 
Test set Batch size weights Cross-study weights Stacking weights 
D 96% 97% 68% 
E 49% 99% 99% 
F 100% 100% 99% 
G 100% 100% 100% 
Table 4.3. Percentages of bootstrap test samples where ensembling yields strictly lower 
mean cross-entropy loss than merging and batch adjustment. Rows indicate validation 




 Finally, the changed results from using six studies to those using four are largely 
due to the fact that study A both contains a different population from the other studies, 
and is highly imbalanced and much larger in size. Having only 16 active TB samples 
among 120 subjects in study A makes it challenging to develop a generalizable predictor 
from study A. However, this predictor is assigned more weight by the stacking regression 
method due to its observations dominating the totality of outcomes across all studies, 
which are aggregated for the stacking regression. For comparison, we upsampled the 
smallest study (D) in the four-study collection to be five times its original size, and 
repeated the experiments. Another set of experiments where we downsampled study A to 
have 16 active and 16 latent patients was also conducted. Comparing the upsampling 
(Figure 4.9) and the downsampling (Figure 4.10) results with the weight assignment in 
the results before, we see that stacking weights assigned to study D indeed increased after 
upsampling, and the weights for study A decreased after downsampling. This suggests 
that the size of the studies may heavily impact the weights for a weighting strategy that is 





Figure 4.9. Mean cross-entropy loss, and weights assigned to learner from each training 
batch after upsampling study D. Study D was upsampled to be five times of its original size, 
resulting in 350 samples in the data. As a result, the stacking regression weights are dominated by 
that assigned to D when it is included in training, which reverses the observation in Figure 4.6 





Figure 4.10. Mean cross-entropy loss, and weights assigned to learner from each training 
batch after downsampling study A. As expected, the stacking weights is no longer dominated 





 We proposed a novel perspective for addressing batch effects when developing 
genomic classifiers. Our proposal is to use multi-study ensemble learning, treating 
batches as separate studies. We provided both realistic simulations and real data 
application examples to compare the ensembling method with the traditional approach, 
which is to analyze all batched together to remove batch effects, and use the adjusted data 
for prediction. We observed in both simulations and real data that, though merging is able 
to generate better performing models when batch effects are modest, ensemble learning 
achieves more robust discrimination in independent validation across different levels of 
severity of batch effects. We explored different training algorithms, different batch sizes 
and number of batches, and observed consistent patterns of such transition. The specific 
level of batch severity where the transition happens differs by the algorithm. 
 The philosophy behind the standard approach of merging and batch adjustment is 
to remove the undesired batch-associated variation from as many of the genomic features 
as feasible, and then use the “cleaned” data in classification as though the batch effects 
never existed. This has been the standard in the literature and can be quite successful 
(Riester et al., 2014, Luo et al., 2010, Engchuan et al., 2016). Multi-study ensemble 
learning provides a different perspective: ensemble weights reward prediction functions 
that, while trained in one batch, continue to predict well in other batches. These are likely 
to avoid using features affected by batch effect, in contrast to cleaning them. 
 Our observations suggest that ensemble learning is a safer choice when the 




performance, while merging and batch correction comes with a risk of major 
performance loss. These are consistent with previous research (Guan et al., 2019), which 
provides theoretical insights into the comparison between merging and ensembling in 
training cross-study learners. 
 In the application example with four studies, we observed broadly consistent 
patterns with those in the simulation. However, in the analysis with six studies, the 
advantages and disadvantages of ensembing and merging is unclear, which is caused by 
studies A and C which contain different populations from the other studies. Especially, 
study A is large in size, causing the stacking regression strategy to assign a high weight 
to the learner trained from A, whenever it is included as a training batch. In such a case 
where one batch is large and confounded with another variable which strongly influences 
the prediction, even ensembling does not provide a model with generalizable 
performance. It is therefore recommended to thoroughly evaluate the available 
information in the data, and identify any confounders for prediction. The studies or 
batches of data to be jointly used should contain the samples and study designs suitable 
for addressing the same biological question. 
 In simulations, we compared ensembles based on a single learning algorithm, to 
one based on multiple algorithms. Though the latter represents the common perspective 
of ensemble in practice, we found that integrating across multiple learning algorithms 
does not necessarily improve prediction performances than using a single algorithm. We 
also compared five kinds of weighting strategies to integrate the predictions. The ranking 




and algorithm. Additionally, there could be ways to further improve the ensemble 
performance by developing other weighting methods that are not considered in this study. 
All ensembles considered are very small, because the number of batches 𝐵 and the 
number or learners 𝐿 are both small. A recent work (Ramchandran et al., 2019) compared 
an ensemble strategy based on RF to one based on cross-study weighting of the 
component trees in the RF, showing improvements from direct reweighting of trees. This 
method may also prove effective in our context, as individual trees are more 
parsimonious than the whole forest, and may more effectively avoid features affected by 
batches.  
 Our study has several limitations. First, the ensemble learning approach requires 
that each batch contains sufficient samples to train a prediction function. This assumption 
may limit our approach to sufficiently large datasets. However, most if not all batch 
effect adjustment strategies require a reasonable number of samples in each batch to 
accurately and robustly estimate batch effects. Having a limited number of samples in a 
batch will negatively affect not only our proposed methods, but also the traditional 
methods based on merging. We speculate that methods like ComBat might, however, be 
able to effectively operate with smaller batches than ensembling. Still, in the context of 
prediction, it is usually challenging to train models on small datasets. 
 We focused on using ComBat for batch effect adjustment after merging. ComBat 
is not the only option, but remains one of the most popular batch effect adjustment 
methods, especially in the case with known sources of batch effect. Our simulations of 




one among many possible models. Using the same batch effect model for data generation 
and analysis provides a lower bound to the effectiveness of our proposal, as any other 
data generating approach would be less favorable to ComBat than the one we used. In 
data from other generating mechanisms, the advantages of ensembling should be more 
pronounced, and may set in at lower levels of batch effects. 
 We provided a realistic application example using the tuberculosis studies. 
Restricted by the study design of these studies, we showed an example with relatively 
small batch sizes in several batches. It would be interesting to further explore our 
approach on data with larger batch sizes, or a larger number of batches. Larger batches 
facilitate both the estimation of batch effects and the training of batch-specific predictors. 
A larger number of batches facilitates learning about the higher-level distributions in 
ComBat, and would afford ensembling a better opportunity to find stable signal across a 
larger number of batches, a strength of the method that is not highlighted here. 
 Related, treating studies as batches mimics a high level of batch differences, for 
the discrepancy across the “batches” in this setting includes both biological and technical 
differences. Thus we include more sources of heterogeneity than normally considered as 
batch effect. Specifically, a batch effect is technically defined as variations originated 
from technical differences across repeated experiments performed on the same platform, 
such as differences in lab environment, protocols or reagents. In our application example, 
however, each batch targets a different population, which means there likely exists 
additional genetic variations across the groups. Also, the TB studies are generated on 




typically considered as batch effects. Despite that, using batch correction software for 
study integration is common in practice, in which studies are often considered as 
“batches” for performing a uniform biological analysis. We believe this example is 
representative of common practice and helpful to illustrate our methodology, and our 
observations offer valuable practical guidelines in addressing batch effects in genomic 
classifier development. Especially, we have shown that when the level of batch 
differences is small, the batch adjustment software may be sufficient for harmonizing the 
negative impact on prediction performance. While ensembling provides a more robust 
option, that is useful when the level of batch effect is strong or unknown. 
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Chapter 5. Conclusions 
 In this dissertation, we present a collection of novel methods, software, 
simulations, and application examples, aiming to understand and address the impact of 
heterogeneity on the analysis of genomic data for personalized medicine applications. We 
started in Chapter 2 from the discussion on batch effects, and introduced improved 
statistical models based on the established ComBat method. We proposed reference-batch 
ComBat and ComBat-Seq. The former is able to leave one batch unchanged, which is 
especially useful for generating and validating fixed biomarkers, and mitigate the 
negative impact of “set bias”. The latter is able to preserve the integer nature of count 
data, making the analysis pipeline more compatible for RNA-Seq studies. We showed in 
both simulations and real data that these proposed methods provide better solutions to 
batch effects than the existing ComBat model in their corresponding batch correction 
scenarios, extending the ComBat software to broader application settings. Then, in 
Chapter 3, we shifted the focus to the more general data heterogeneity, and discussed its 
impact on developing genomic prediction models with the capacity to translate from 
academic development to facilitating clinical diagnosis and treatment. We generated 
realistic simulations to explore three commonly assumed sources of study heterogeneity, 
and their impact on prediction model performances in independent validation. Our 
observations provide insights for understanding the associations of heterogeneity with the 
validation of models, and facilitates developing robust prediction models. By providing 
the simulatorZ software to automate the bootstrapping and cross-study validation 




and its impact. Finally, in Chapter 4, we proposed a new perspective of addressing batch 
effects with cross-study ensemble learning in classification problems. Rather than the 
traditional approaches of merging and removing batch effects, our framework trains 
separate models from each batch and integrates the predictions. We compared merging 
with ensembling in simulations and applications to real data. Our results provided 
practical guidelines in developing prediction models with generalizable performances to 





Appendix A: Data preprocessing for the genomic studies for Chapter 3 
Data cleaning for the microarray studies 
 The simulations were first performed on two collections of cancer microarray 
studies, with the first group being the curated breast cancer datasets (Bernau et al., 2014, 
Haibe-Kains et al., 2012). This compendium of datasets has censored disease and 
metastasis-free survival (DMFS) response and estrogen-receptor positive breast cancer 
individuals. Datasets originating from more than one study were separated into their base 
sets. 10 base sets involved in the previous study were considered for inclusion: CAL, 
MAINZ, MSK, EXPO, TRANSBIG, UNT, VDX, MDA4, SUPERTAM_HGU133A and 
SUPERTAM_HGU133PLUS2. The latter four were referred to as VDX3, MDA5, and 
TAM in the previous work (Bernau et al., 2014). MDA4 and EXPO were excluded for 
the lack of the DMFS information. We linearly scaled the gene expressions based on the 
2.5% and 97.5% quantiles. Among genes shared across the remaining 8 datasets, the 40% 
with the highest variances were selected, which led to 5307 genes. Samples from 
SUPERTAM_HGU133A that are duplicated in VDX were removed. Missing expression 
values were imputed by the K-nearest neighbors approach (Troyanskaya et al., 2001). 
 Available clinical and pathological covariates in these datasets include PGR and 
HER2 expressing status, histological grade, tumor size, nodal status, and patient age at 
diagnosis. Age and tumor size were dichotomized at 50 years and 2cm, respectively 
(Haibe-Kains et al., 2012), and grade was maintained at three levels (low/medium/high) 
as in the original datasets. PGR, nodal status and HER2 were only available in 5, 4, and 2 




available clinical factors. Patients missing any of these three clinical factors, or with zero 
follow-up, were excluded. 
 Finally, datasets with fewer than 40 individuals were removed. The remaining 7 
datasets are referred to as the “original datasets”, with 1021 patients combined. 
 The other collection, of ovarian cancer microarray datasets, is available through 
the curatedOvarianData Bioconductor package (Ganzfried et al., 2013). To select a 
group of studies for simulation from curatedOvarianData, we filtered datasets with at 
least 1000 genes, 40 individuals and 15 events. Batch effects were adjusted within each 
dataset when the batch information was available, and the expression values were 
standardized with z-score scaling. Missing values in the expression matrices were 
imputed by the K-nearest neighbors approach (Troyanskaya et al., 2001). We then took 
the overlapping genes across all studies, and removed all genes with a standard deviation 
below the 60% quantile in every selected dataset, which resulted in 7484 gene features. 
 Patients with late-stage, high-grade cancer were included. The datasets contain 
patient age and debulking as available clinical covariates. Samples with missing values in 
these covariates or the outcome were removed. The patient age was dichotomized at 70 
years. After cleaning, 5 microarray datasets were selected as the “original datasets” for 
ovarian cancer, with 935 patients in the collection. 
Feature selection and model training for metagenomic studies 
 We used gene families from these data as explanatory variables in the prediction 
models. The original datasets contain over 1 million overlapping features. To reduce the 




eliminated features with close-to-zero values across all samples within each study. Then, 
we included only 60% features with high variance in each study, and took the 
overlapping features across all studies after the filtering. This reduces the number of 
features to 300K. We then selected features by training random forest (Breiman, 2001) on 
each study, and recording the feature importance in terms of the average decrease in Gini 
impurity (Friedman et al., 2001). Each feature has 3 Gini importance scores, one for each 
study, after training random forest. We took the average of the 3 scores as the final 
importance score for the features. At the end, we ranked all features by their importance 
scores, and selected the top 800 most important features to be used in the analysis. The 
number 800 was determined via grid search - we trained random forest with the top-K 
most important features, and estimated accuracy on the out-of-bag samples within each 
study (K ranges from 100 to 2000). We selected the K which yields the best average out-
of-bag accuracy over the 3 studies. 
 Finally, we used the selected features to train the true logistic regression models. 
Models were trained with the Elastic Net (Zou and Hastie, 2005) penalty. Probabilities of 





Appendix B: Ensemble weighting methods for Chapter 4 
 We fit each of 𝐿 learning algorithms to each of the 𝐵 batches in the training set. 
Models obtained by fitting algorithm 𝑘 on batch 𝑏 is denoted as ?̂?𝑏
𝑘(𝑥), and their 
corresponding weight is 𝑤𝑘𝑏 . We compare five kinds of weights. 
• Simple average. Weights for all models are constant. 𝑤𝑘𝑏 = 1/𝐿𝐵 
• Batch-size weighted average. 𝑤𝑘𝑏 = 𝑛𝑏/(𝐿 ∑ 𝑛𝑟𝑟 ), where 𝑛𝑟 is the sample size 
of batch 𝑟. Under these weights, the larger batches get higher weights. 
• Cross-study weights. We use each model ?̂?𝑏
𝑘(𝑥), to make predictions in each of 
the other batches aside from 𝑏. In doing so, we construct a matrix of model 







𝑘(𝑥𝑗) + (1 − 𝑦𝑗) log(1 − ?̂?𝑖
𝑘(𝑥𝑗))), which refers to the 
mean cross-entropy loss of predictions on batch 𝑗, using model ?̂?𝑖
𝑘. We then 
summarize these matrices across the batches for prediction (𝑗), to obtain the 
unscaled weight for model ?̂?𝑏








. Finally, the scaled 







where 𝐶 is a normalization factor which ensures that the weights have a sum of 1. 
This approach assigns zero weight to the model with the worst average 




generalization performances estimated using the remaining batches within the 
training set). 
• Aggregated regression weights. We use each model to make predictions in each 
other batch. As a simplified notation, we use 𝑝𝑖𝑗
𝑘 = ?̂?𝑖
𝑘(𝑥𝑗) to describe the 
predicted probabilities on batch 𝑗 using model ?̂?𝑖
𝑘. Note that 𝑗 can equal to 𝑖 in 
this case. We calculate the coefficients of non-negative least square regression for 




𝑘 , … , 𝛽𝐵𝑗





𝑘 , … , 𝑝𝐵𝑗
𝑘 ) is a matrix of predicted probabilities, with each 
column being predictions using model trained from each batch. The weights are 
then defined as the batch-size weighted average of vector 𝛽𝑗
𝑘: 






or equivalently, 𝑤𝑘𝑏 = ∑ 𝑛𝑗𝑗 ∗ 𝛽𝑏𝑗
𝑘 / ∑ 𝑛𝑗𝑗 . 
• Stacking regression weights. Stacking weights are constructed in similar ways as 
the aggregated weights, only that now, we stack the labels and predictions for all 
training batches. We use 𝑌 = (𝑦1
𝑇 , 𝑦2
𝑇 , … , 𝑦𝐵
𝑇)𝑇, and 𝑃 = (𝑃1
𝑘 , 𝑃2
𝑘 , … , 𝑃𝐵
𝑘) to 
denote the stacked labels from all training batches and predictions in these 
batches. 𝑃𝑏
𝑘 = (𝑝𝑏1
𝑘 𝑇 , 𝑝𝑏2
𝑘 𝑇 , … , 𝑝𝑏𝐵
𝑘 𝑇)
𝑇
 is the stacked predictions on every batch, 
using model ?̂?𝑏
𝑘 from batch 𝑏. The weights are then computed through a single 
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